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ABSTRACT

Title: Mechanisms of Hdac2 function in the regulation of adult cardiac hypertrophy
and embryonic myocyte proliferation

Wenting Zhu

Jonathan A. Epstein

HDACs can modify the structure and function of chromatin to regulate gene
expression and can also modify many non-histone proteins that regulate cell function
and signaling. HDACs have attracted increasing interest because they are involved in
a variety of physiologic and pathophysiologic processes including stem cell
maintenance, differentiation, cancer, inflammation and cardiac diseases. In the
absence of Hdac2, mice display myocyte hyper-proliferation during embryonic
development and resistance to cardiac hypertrophy in adulthood. This doctoral
dissertation examines the function of two Hdac2 downstream targets, Inpp5f and
Gata4, in regulating adult cardiac hypertrophy and embryonic myocyte proliferation,
respectively. My results suggest that Inpp5f is an important endogenous modulator of
the cardiac response to stress. I also performed studies to show that, in the absence of
Hdac2 in the embryonic heart, hyper-acetylated Gata4 is responsible for myocyte
hyper-proliferation. These findings provide a framework for understanding the role of
Hdac2 in embryonic heart development and adult cardiac diseases.
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Chapter 1 Introduction
In this dissertation, I explore the mechanisms of histone deacetylase 2 (Hdac2)
in regulating adult cardiac hypertrophy and embryonic cardiomyocyte proliferation.
Previous work suggests that Hdac2 promotes hypertrophy associated with increased
phosphoinositide 3-kinase (PI3K)/Akt signaling and Hdac2 negatively regulates the
expression of a novel phosphoinositide 5-phosphatase, inositol polyphosphate-5phosphatase 5 F (Inpp5f) (Trivedi et al., 2007). The activity of this protein is specific
for PtdIns(4,5)P2 and PtdIns(3,4,5)P3 (Minagawa et al., 2001). In chapter 2, I
describe experiments to study the role of Inpp5f in regulating hypertrophy. These
studies led to the discovery that Inpp5f is an important endogenous modulator of
cardiac responses to stresses and it regulates the hypertrophy process through
regulating the PI3K/Akt pathway. Another interesting phenotype of Hdac2 knockout
mice is hyper-proliferation of myocytes during embryonic development. In chapter 3,
I investigated the role of Hdac2 in regulating GATA-binding factor 4 (Gata4), a
crucial regulator of cardiomyocytes proliferation (Rojas et al., 2008; Zeisberg et al.,
2005). This introductory chapter will summarize our current knowledge of PI3K/Akt
signaling during cardiac hypertrophy, Gata4 function during heart development and
other areas of interest related to my thesis project.
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1.1 Cardiac hypertrophy

Cardiovascular disease remains the number one cause of mortality in the
Western world, with heart failure representing the fastest growing subclass over the
past decade (Heineke and Molkentin, 2006; Hobbs, 2004; Kannel, 2000; Levy et al.,
2002). For example, there are approximately 5 million Americans currently diagnosed
with heart failure, which is characterized by a 5-year survival rate of approximately
50%, resulting in a total economic impact as high as 100 billion dollars per year
(Heineke and Molkentin, 2006).

Cardiac hypertrophy is an early milestone during the clinical course of heart
failure and an important risk factor for subsequent cardiac morbidity and mortality
(Hunter and Chien, 1999). During cardiac hypertrophy, individual myocytes grow in
length and/or width as a means of increasing cardiac pump function and decreasing
ventricular wall tension (Heineke and Molkentin, 2006). Although hypertrophy is
initially beneficial, permitting enhanced cardiac output, it can ultimately become
deleterious and result in cardiomyopathy, heart failure and sudden death (McKinsey
and Olson, 1999). It can occur in response to normal physiological stimuli, as during
pregnancy and exercise, or may be associated with disease-inducing stimuli leading to
cardiac dilatation and congestive heart failure (Frey and Olson, 2003). The defining
features of hypertrophy are an increase in cardiomyocyte size, enhanced protein
synthesis, and a higher organization of the sarcomere. It is not accompanied by cell
proliferation or cardiac cell renewal. The changes in cellular phenotype are preceded
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and accompanied by the reinduction of the so-called fetal gene program, including
natriuretic peptide precursor type A (Nppa) (encoding atrial natriuretic factor, ANF),
Myh7(encoding β-myosin heavy chain), and Nppb (encoding BNP) (Frey and Olson,
2003).

Cardiac hypertrophy requires coupling of intracellular signal transduction
systems with transcription factors that activate and maintain the hypertrophic program
(McKinsey and Olson, 1999). Over the past years, signaling pathways involving
growth factors, G proteins, mitogen-activated protein kinases and calcium-responsive
phosphatases have emerged as critical regulators of cardiac hypertrophy (Dorn and
Force, 2005; Gupta et al., 2007; McKinsey and Olson, 1999). The PI3K/Akt signaling
network is of particular interest because many components in this pathway have been
shown to modulate myocyte survival, hypertrophy, contractility, electrophysiology,
metabolism, mechanotransduction and coronary angiogenesis (Oudit and Penninger,
2009). The following sections will describe these in detail and discuss the
experimental data supporting a role for the PI3K/Akt pathway in the hypertrophic
process.

Another particularly important phenomenon involved in gene expression is
histone acetylation/deacetylation which is mediated by histone acetyl transferase
(HAT) and HDAC (Ekwall, 2005). The balance between HAT and HDAC seems to
play an especially important role in the control of gene expression, which, according
to recent evidence, will also affect the hypertrophic process (Antos et al., 2003; Chang
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et al., 2004; Kong et al., 2006; Kook et al., 2003; Montgomery et al., 2007; Trivedi et
al., 2007; Zhang et al., 2002).

Despite all the current knowledge of hypertrophy, the cellular mechanisms that
regulate the hypertrophic response to agonists or to stretch remain poorly understood,
and treatments to combat hypertrophy are also lacking. My study will be directly
relevant for the development of new therapies for cardiac hypertrophy and heart
failure that target intrinsic abnormalities in signaling pathways and transcriptional
programs within the diseased cardiac myocyte.

1.2 Overview of the PI3K/Akt signaling pathway

The PI3K/Akt signaling network (outlined in Figure 1.1) is crucial to widely
divergent physiological processes that include cell cycle progression, differentiation,
transcription, translation, apoptosis and metabolism (Martelli et al., 2006). PI3K can
be activated by several receptor tyrosine kinases (RTKs), such as the insulin growth
factor-1 (IGF-1) receptor (Walsh, 2006), as well as G protein-coupled receptors
(GPCRs), including α- (Schluter et al., 1998) and β2-adrenergic receptors (Chesley et
al., 2000; Zhu et al., 2001). Upon ligand binding, PI3K is translocated to the
membrane, where it converts the plasma-membrane lipid phosphatidylinositol-4,5bisphosphate

(PtdIns(4,5)P2,

PIP2)

to

phosphatidylinositol-3,4,5-trisphosphate

(PtdIns(3,4,5)P3, PIP3). PIP3 then recruits both Akt/protein kinase B (PKB) and its
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activator phosphoinositide-dependent protein kinase-1 (PDK1) to the membrane by
binding to their pleckstrin homology (PH) domains, leading to phosphorylation and
activation of Akt (Matsui et al., 2003). Activation of Akt then leads to activation of
mammalian target of rapamycin (mTOR), a central regulator of protein synthesis. Akt
also phosphorylates and inhibits a kinase, glycogen synthase kinase 3β (Gsk3β) (Dorn
and Force, 2005).

The PI3K/Akt pathway is highly regulated. The termination of PI3K/Akt
signaling by degradation of PtdIns(3,4,5)P3 can be mediated by at least two different
types of phosphatases,

3-ptases (inositol polyphosphate 3-phosphatases), which

converts PtdIns(3,4,5)P3 back to PtdIns(4,5)P2, and 5-ptases (inositol polyphosphate
5-phosphatases), which generates PtdIns(3,4)P2 (Ooms et al., 2009).

1.3 Inositol polyphosphate phosphatases

Phosphoinositides (PIs) are quantitatively minor phospholipids of cell
membranes but their metabolism is highly active and accurately controlled by specific
PI kinases and phosphatases (Pendaries et al., 2003). The importance of these PI
phosphatases in cell regulation is illustrated by their involvement in human diseases
such as cancer and diabetes (Blero et al., 2007) (Table 1.1). Cellular levels of
PtdIns(3,4,5)P3 are about 50 nM in unstimulated cells but increase 40 fold within
seconds to within 2 µM following agonist stimulation (Insall and Weiner, 2001;
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Stephens et al., 1993). PtdIns(3,4,5)P3 is dephosphorylated within seconds by
phosphatases. The most well-studied PtdIns(3,4,5)P3 3-ptase is PTEN (phosphatase
and tensin homolog deleted on chromosome ten) (Cantley, 2002; Oudit et al., 2004),
while the 5-ptases are a large family comprising 10 mammalian and 4 yeast members
(Astle et al., 2006).

1.3.1 PTEN

PTEN was first identified as tumor suppressor gene localized on chromosome
10q23 (Li et al., 1997; Steck et al., 1997). Human germline mutations in PTEN are
associated with several rare autosomal dominant cancer predisposition syndromes
including Cowden disease (Knobbe et al., 2008; Liaw et al., 1997; Marsh et al., 1998)
(Table 1.1). Mice homozygous for targeted deletions within the PTEN gene (PTEN -/-)
die during embryonic development (between Days 6.5 and 9.5), while heterozygous
mice develop normally but are prone to a wide range of tumor types including cancers
of the breast, thyroid, endometrium and prostate as well as T cell lymphomas (Di
Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic et al., 1998; Suzuki et al.,
1998). PTEN +/- mice also develop signs of autoimmune disease (Di Cristofano et al.,
1999).

The main physiological substrates of PTEN are PtdIns(3,4,5)P3 and possibly
PtdIns(3,4)P3. PTEN is considered the principal regulator of basal cellular
PtdIns(3,4,5)P3 levels (Leslie and Downes, 2002). A lot of studies using PTEN null
cell lines have been done to study the effects of PTEN activity on cellular
6

PtdIns(3,4,5)P3 (Leslie and Downes, 2002; Maehama and Dixon, 1998; Stambolic et
al., 1998; Sun et al., 1999). Deletion of PTEN in murine fibroblasts and embryonic
stem cells results in greatly elevated unstimulated PtdIns(3,4,5)P3 levels (Stambolic et
al., 1998; Sun et al., 1999). Similar results have also been obtained with human tumor
cell lines lacking PTEN, and PtdIns(3,4,5)P3 levels are reduced dramatically upon reexpression of the phosphatase (Taylor et al., 2000). HPLC analysis of labeled cellular
PIs has also shown that PtdIns(3,4)P2 levels appear similarly high and decrease with
PTEN re-expression (Taylor et al., 2000). In addition to this direct evidence, a wealth
of data has shown greatly increased activity of the downstream kinase Akt in many
PTEN null cell types, and that this activity is reduced by expression of PTEN (HaasKogan et al., 1998; Li and Sun, 1998; Li et al., 1998; Myers et al., 1998; Nakashima
et al., 2000; Persad et al., 2000; Ramaswamy et al., 1999; Stambolic et al., 1998; Sun
et al., 1999; Wu et al., 1998). Cardiac specific PTEN knockout mice have also been
generated (Crackower et al., 2002) and the detailed phenotypes will be reviewed later.

1.3.2 Inositol polyphosphate 5-phosphatases

1.3.2.1 Src homology 2 (SH2) domain-containing inositol polyphosphophate 5phosphatases 1 and 2 (SHIP and SHIP2)

SHIP and SHIP2 are capable of removing the 5-phosphate from PtdIns
(3,4,5)P3 to yield PtdIns (3,4)P2. SHIP is expressed predominantly in hematopoietic
cells where it is an important negative regulator of cytokine signaling. SHIP-/- mice
have shorter life span associated with massive myeloid cell infiltration of the lungs
7

and numerous hematopoietic abnormalities (Helgason et al., 1998; Liu et al., 1998).
SHIP2 is more widely expressed, most highly in brain, skeletal muscle and heart
(Astle et al., 2006). It plays an important role in insulin signaling and obesity
regulation (Grempler et al., 2007; Sleeman et al., 2005). When exposed to a normal
diet, SHIP2-/- mice exhibit a basal metabolic rate similar to wild type controls
However, SHIP2-/- mice are highly resistant to weight gain when placed on a high-fat
diet. Under these conditions, SHIP2-/- mice demonstrate an increased metabolic rate
and show no increase in serum lipids, insulin or glucose levels. The liver and skeletal
muscle of the SHIP2-/- mice shows evidence of enhanced activation of the Akt
signaling pathway (Sleeman et al., 2005). Genotypic analyses of diabetic rat and
human subjects have found a significant association between SHIP2 gene
polymorphisms and type 2 diabetes (Kagawa et al., 2005; Kaisaki et al., 2004; Marion
et al., 2002).

1.3.2.2 Synaptojanin 1/2

Two synaptojanin isoforms (1 and 2) are 5-phosphatases which are able to
hydrolyze PtdIns(3,4,5)P3 and PtdIns(4,5)P2 (McPherson et al., 1996; Woscholski et
al., 1997). Synaptojanin 1 is a nerve terminal protein of 145 kDa that appears to
participate with dynamin in synaptic vesicle recycling (McPherson et al., 1996).
Synaptojanin 1-deficient mice die shortly after birth due to neurological defects
(Cremona et al., 1999). Linkage analysis for bipolar disorder identified synaptojanin 1
as a candidate gene (Saito et al., 2001; Stopkova et al., 2004). The cDNA encoding
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Synaptojanin 2 was identified by polymerase chain reaction using degenerate primers
(Nemoto et al., 1997). It regulates the early stages of endocytosis. Depletion of
synaptojanin 2 in A-549 cells causes a decrease in the number and size of vesicles at
all stages of endocytosis (Rusk et al., 2003). Targeted depletion of synaptojanin 2 in
glioblastoma cells also inhibits the formation of lamellipodia and invadopodia, and
cell migration and invasion (Chuang et al., 2004).

Both Synaptojanin 1 and 2 have a Sac domain, which contains phosphatase
activity (Guo et al., 1999). The Sac domain has approximately 400 amino acid
residues and is defined by seven conserved motifs which appear to define the catalytic
and regulatory regions of the phosphatase (Hughes et al., 2000). The highly conserved
sequence RXNCXDCLDRTN in the sixth motif is proposed to be the catalytic core of
the Sac domain phosphatases. The CX5R(T/S) motif within this sequence is also
found in a number of metal-independent protein phosphatases and inositol
polyphosphate phosphatases and is known to be a phosphatase catalytic site (Guo et
al., 1999; Hughes et al., 2000). Interestingly, the Sac domain of the yeast
synaptojanin-like protein Inp51p does not exhibit phosphatase activity, and the
cysteine, arginine and threonine/serine residues are absent from the CX5R(T/S) motif
of this protein, being replaced by alanine, lysine and proline respectively. Furthermore,
mutations of the first conserved aspartate residue in the RXNCXDCLDRTN sequence
as seen in the yeast sac1-8 and sac1-22 mutant alleles were demonstrated to inactivate
the Sac1p functions (Hughes et al., 2000; Kearns et al., 1997; Zhong and Ye, 2003).
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Together, this evidence suggests that the RXNCXDCLDRTN motif could well
represent the catalytic core of the Sac phosphatases.

1.3.2.3 Inositol polyphosphate-5-phosphatase F (Inpp5f)

Inpp5f is a novel Sac domain-containing phosphoinositide 5-phosphatase whose
activity is specific for PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in vitro (Minagawa et al.,
2001). As I will discuss later in the next chapter, I was able to identify the seven
conserved motifs and the sixth conserved region of Inpp5f in both mouse and human
has the highly conserved CX5R(T/S) motif, suggesting it is catalytically active. It is
widely expressed in several tissues including brain, heart, skeletal muscle, kidney
(Minagawa et al., 2001). However, its in vivo role has not been characterized prior to
this study.

1.4 PI3K/Akt signaling in cardiac hypertrophy

The PI3K/Akt pathway is essential for both basal cell growth as well as
adaptive (physiologic) and maladaptive (pathologic) hypertrophy (Oudit et al., 2004).
Several transgenic and knockout models support a fundamental role of this pathway in
the regulation of hypertrophy (Summarized in Table 1.2).
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1.4.1 PI3K

PI3K inhibitors attenuate basal rates of protein synthesis in unstimulated cells
and abolish increases in protein synthesis induced by insulin in neonatal
cardiomyocytes (Pham et al., 2000). The complete knockout of p110α, the catalytic
subunit of PI3Kα, was lethal at E9.5-E10.5 due to a severe proliferation defect (Bi et
al., 1999) and therefore was of limited usefulness for cardiac studies. Cardiac specific
over-expression of constitutively active PI3Kα (CA-PI3Kα) in mice results in
enlarged hearts owing to increased cardiomyocyte size (Crackower et al., 2002; Shioi
et al., 2000), whereas over-expression of dominant negative PI3Kα (DN-PI3Kα)
produces smaller hearts with reduced cardiomyocyte size without affecting cell
number (Crackower et al., 2002; McMullen et al., 2003; Shioi et al., 2000). These
changes in heart size are associated with corresponding alterations in Akt, and p70S6kinase (p70S6K) phosphorylation and activities. These studies suggest a positive role
of PI3K in cardiac growth.

1.4.2 PDK1

PDK1 is a ubiquitously expressed 67 kDa kinase containing a N-terminal
catalytic domain and a C-terminal PH domain (Storz and Toker, 2002; Toker and
Newton, 2000). It is central in the PI3K signaling pathway and whole-body knockout
of PDK1 is associated with embryonic lethality (Lawlor et al., 2002) while cardiac
specific PDK1 ablation leads to reduced cardiomyocyte size and cardiomyopathy (Ito
et al., 2009; Mora et al., 2003).
11

1.4.3 Akt/PKB

Akt is a serine/threonine protein kinase family comprising three closely related,
highly conserved isoforms: Akt1 (PKBα), Akt2 (PKBβ) and Akt3 (PKBγ) (Chan et al.,
1999; Oudit and Penninger, 2009). Akt2 and Akt3 show 81 and 83% amino acid
identity, respectively, with Akt1 (Shioi et al., 2002). Only Akt1 and Akt2 are highly
expressed in the heart (Dorn and Force, 2005). The activity of Akt is primarily
controlled by PI3K and PTEN via the modulation of PtdIns(3,4,5)P3 levels (Maehama
et al., 2001; Stambolic et al., 1998; Vanhaesebroeck et al., 2001)

Several Akt knockout and transgenic mouse models have been generated to
study the physiological roles of Akt. Targeted disruption of the Akt1 gene in mice
results in a growth retardation phenotype. They have a 20% reduction in body size,
with a concomitant reduction in heart size (Chen et al., 2001; Cho et al., 2001b). More
recently, Akt1 null mice were shown to be resistant to exercise-induced cardiac
hypertrophy. Furthermore, adult murine cardiac myocytes are resistant to IGF-1
stimulated protein synthesis in vitro suggesting that Akt1 deficiency in myocytes
account for the reduction in heart growth in this mouse model (DeBosch et al., 2006b).
It may be useful to confirm these findings in a cardiac-specific Akt1 knockout model.
Akt2 null mice exhibit insulin resistance and depending on genetic background, mild
growth retardation (Cho et al., 2001a; Garofalo et al., 2003). Consistent with this, a
mutation in the human AKT2 gene has been shown to be associated with autosomal
dominant inheritance of severe insulin resistance and diabetes mellitus (George et al.,
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2004). Akt2 null mice displayed normal cardiac growth responses to provocative
stimulation, including ligand stimulation of cultured cardiomyocytes, pressure
overload by transverse aortic constriction, and myocardial infarction. However, Akt2
is absolutely required for the maintenance of normal cardiac glucose metabolism and
for cardiomyocyte survival in response to ischemic injury (DeBosch et al., 2006a).
Akt3 null mice have smaller brain size due to the reduction in both cell size and cell
number. However, they do not show the general growth retardation phenotype
(Easton et al., 2005; Tschopp et al., 2005). Thus, data from the available Akt
knockout models support a critical role specifically for Akt1 in normal growth of the
heart. Akt1/Akt2 double-null animals die shortly after birth due to defects in multiple
tissues including skeletal muscle, bone and skin (Peng et al., 2003). Akt1/Akt3
double-mutant mice die by E12 with more severe developmental defects in the
cardiovascular and nervous systems (Yang et al., 2005). Thus, the phenotypes of these
compound mutants suggest functional redundancy among the three Akt proteins.

In transgenic studies, myristoylated Akt1 (membrane-targeted Akt1, myr-Akt1)
(Cook et al., 2002; Matsui et al., 2002; Shiojima et al., 2005) or a phosphorylation
mimicking mutant of Akt1 (Akt1 T308D/S473D) (Shioi et al., 2002) or PH domain
mutant of Akt1 (Akt1 E40K), which has increased affinity to phospholipids,
(Condorelli et al., 2002; Kim et al., 2003) has been used as a constitutively active (CA)
Akt1. One common phenotype associated with overexpression of CA-Akt1 in the
heart is cardiac hypertrophy with an increase in myocyte size (Condorelli et al., 2002;
Kim et al., 2003; Matsui et al., 2002; Shioi et al., 2002; Shiojima et al., 2005). And
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the CA-Akt1 T308D/S473D mutant protein circumvented cardiac growth retardation
induced by a KD-PI3K mutant protein (Shioi et al., 2002), suggesting Akt functions
downstream of PI3K. In contrast, mice over-expressing kinase dead (KD)-Akt1
(K179M), in which the critical ATP binding site was mutated, has similar heart and
myocyte size as their control littermates. However, The KD-Akt1 mutant protein
attenuated the CA-PI3K-induced overgrowth of the heart (Shioi et al., 2002). Cardiacspecific myristoylated Akt3 transgenic mice also exhibited marked cardiac
hypertrophy (Taniyama et al., 2005).

1.4.4 Gsk3β

Gsk3β was initially identified as a kinase that phosphorylates and inactivates
glycogen synthase but is now recognized as a regulator of multiple processes
including development, tumorigenesis, and metabolism (Doble and Woodgett, 2003).
Gsk3β is constitutively active in unstimulated cells where it phosphorylates and
negatively regulates most of its substrates. In response to RTK/GPCR activation,
phosphorylation of the serine-9 residue in the N-terminal region of Gsk3β by Akt
inhibits Gsk3β thereby leading to diverse effects (Doble and Woodgett, 2003; Toker
and Cantley, 1997). Whole-body knockout of Gsk3β leads to embryonic lethality by
E16.5 due to severe liver degeneration (Hoeflich et al., 2000). Cardiac specific
overexpression of wildtype Gsk3β (Michael et al., 2004) or expression of Gsk3β (S9A)
(Antos et al., 2002) reduces maturational growth of the heart, and reduces the cardiac
hypertrophy induced by isoproterenol (ISO) infusion, transverse aortic constriction
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(TAC) or overexpression of constitutively activated calcineurin (Antos et al., 2002),
confirming that GSK-3β functions as a negative regulator of hypertrophy in vivo.
Furthermore, inducible expression of Gsk3β (S9A) in the adult heart reduces the
extent of established hypertrophy produced by TAC, as assessed by left ventricular
weight/body weight (Sanbe et al., 2003). In contrast, cardiac overexpression of
dominant-negative Gsk3β (K85M/K86I) results in hypertrophy (Hirotani et al., 2007).

Several potential mechanisms are proposed for the negative regulatory role of
Gsk3β in cardiac hypertrophy. First, Gsk3β may attenuate cardiac hypertrophy by
phosphorylating and inducing nuclear export of NFAT (nuclear factor of activated Tcells) (Heineke and Molkentin, 2006). Because calcineurin, a calcium-dependent
phosphatase and a transducer of cardiac stress signals, induces of hypertrophy through
dephosphorylation and nuclear import of NFAT (Molkentin et al., 1998),
phosphorylation of NFAT by Gsk3β masks its nuclear localization sequence and
antagonizes the hypertrophic effects of calcineurin. Indeed, constitutively active
Gsk3β inhibits endothelin-1-induced NFAT nuclear import (Haq et al., 2000), and
concomitant Gsk3β overexpression markedly reduces hypertrophy of calcineurintransgenic mice (Antos et al., 2002). Second, because Gsk3β induces nuclear export
of Gata4 (Morisco et al., 2001) and reduces transcriptional activity of myocardin
(Badorff et al., 2005), both of which are transcription factors implicated in
hypertrophic responses of myocytes (Perrino and Rockman, 2006; Pipes et al., 2006),
Gsk3β may attenuate cardiac hypertrophy by suppressing the activities of these
transcription factors. Third, Gsk3β inhibits initiation of protein translation by
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negatively regulating eukaryotic translation initiation factor 2B (eIF2B) (Dorn and
Force, 2005) and enhanced protein synthesis is an important feature during
hypertrophy. In cultured cardiac myocytes, it was shown that phosphorylation of
eIF2B by Gsk3β is critical for anti-hypertrophic effects of Gsk3β (Hardt et al., 2004).
eIF2B phosphorylation is also increased in the heart of Gsk3β transgenic mice
(Michael et al., 2004).

1.4.5 mTOR

mTOR is a 289 kDa evolutionarily conserved serine/threonine kinase that is
inhibited by the drug rapamycin (Harris and Lawrence, 2003; Schmelzle and Hall,
2000). The best characterized function of mTOR in mammalian cells is regulation of
translation (Inoki et al., 2005). Two most important downstream targets of mTOR are
ribosomal S6 kinase (S6K) and eukaryote initiation factor 4E binding protein 1
(4EBP1), which are key regulators of protein translation (Inoki et al., 2005).
Rapamycin has been shown to decrease agonist-induced hypertrophy in vitro
(Sadoshima and Izumo, 1995) and load-induced hypertrophy in mice (Shioi et al.,
2003). Cardiac hypertrophy induced by Akt overexpression is effectively blocked by
rapamycin treatment (Shioi et al., 2002; Shiojima et al., 2005).

1.4.6 PTEN

The role of PTEN in cardiac hypertrophy has been studied in both cultured
myocytes and mouse models. In neonatal cardiomyocytes, expression of DN-PTEN
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increases protein synthesis and cell size associated with elevated level of phosphoAkt,,

while overexpression

of wildtype PTEN impaired

these

responses

(Schwartzbauer and Robbins, 2001). Cardiac specific knockout of PTEN increases
phospho-Akt, phospho-Gsk3β and phospho-p70S6K levels, resulting in increased
cardiomyocyte and heart size.

And co-expression of DN-p110α

reverses the

phenotype (Crackower et al., 2002).

1.5 Overview of histone deacetylases

Gene expression is regulated not only at the level of individual promoters, but
also, at a more global level, by modulation of chromatin structure. Modification of
core histones, around which DNA is wrapped, affects the packaging of nucleosomes
and the accessibility of specific regions of DNA to transcription factors and the basal
transcriptional machinery. Histone acetylation, mediated by HATs, results in
chromatin relaxation and transcriptional activation (Gallinari et al., 2007), while
HDACs induce deacetylation, chromatin condensation, and transcriptional repression
(Ekwall, 2005; Johnson and Turner, 1999). HDACs lack intrinsic DNA binding
ability and are recruited to target genes via their incorporation into large multiprotein
transcriptional complexes as well as direct association with transcriptional activators
or repressors (Grunstein, 1997). There are 11 HDACs encoded by mammalian
genome, which can be classified into four families (class I, IIa, IIb and IV). The class
I HDAC family consists of HDAC1, 2, 3 and 8, which are expressed ubiquitously and
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consist mainly of a deacetylase domain with short amino- and carboxy-terminal
extensions (Ekwall, 2005; Haberland et al., 2009). Class IIa HDACs (HDACs 4, 5, 7,
and 9) have large N-terminal extensions in addition to the catalytic domain, and they
have restricted express pattern. The extensions have conserved binding sites for the
transcription factor myocyte enhancer factor 2 (MEF2) and the chaperone protein 143-3 (Haberland et al., 2009). HDAC5 and HDAC9 are highly expressed in muscle,
heart and brain (Chang et al., 2004; Zhang et al., 2002). HDAC4 is mainly found in
the brain and growth plates of the skeleton (Vega et al., 2004), and HDAC7 is
expressed in endothelial cells and thymocytes (Chang et al., 2006). The class IIb
family consists of HDAC6 and HDAC10. HDAC6 mainly exists in cytoplasm in
mammalian cells (Zhang et al., 2008). Little is known about HDAC10. HDAC11 is
the sole class IV HDAC, which has been shown to regulate the expression of
interleukin 10 and immune tolerance (Villagra et al., 2009).

Mammalian HDACs are also able to deacetylate non-histone targets.
Acetylation has been shown to affect protein stability, DNA binding, transcription
activation, protein interactions, localization and enzymatic activity (Spange et al.,
2009). For example, acetylation of p53 activates its sequence-specific DNA binding
activity and consequently increases activation of its target genes (Gu and Roeder,
1997), while deacetylation of p53 by HDAC1 represses p53-dependent transcriptional
activation and modulates p53-mediated cell growth arrest and apoptosis (Luo et al.,
2000). As p53 acetylation might favor DNA binding and transcriptional activation,
this mechanism has likewise been suggested for the transcription factors c-Myb (Sano
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and Ishii, 2001; Tomita et al., 2000), GATA factors (Boyes et al., 1998; Hayakawa et
al., 2004; Yamagata et al., 2000), E2F1 (Martinez-Balbas et al., 2000; Marzio et al.,
2000), MyoD (Sartorelli et al., 1999) and many others.

1.6 HDACs in regulating cardiac hypertrophy

The roles of HDACs in cardiac hypertrophy have been investigated through
several gene-targeting studies in the mouse. Mice lacking either HDAC5 or HDAC9
are normal at early age. However, by about 8 months of age, mutant animals develop
spontaneous cardiac hypertrophy that appears to reflect sensitization to age-related
cardiac insults. HDAC5 and HDAC9 mutant mice also develop grossly enlarged
hearts in response to pressure overload or constitutive cardiac activation of
calcineurin (Chang et al., 2004; Zhang et al., 2002). In HDAC9 knockout animals,
MEF2 activity is increased (Zhang et al., 2002). It is proposed that HDAC5 and 9 can
interact with MEF2 through the N terminal extension and thus lead to repression of
hypertrophic genes, while class I HDACs lack this domain and fail to directly regulate
the activity of MEF2 (Lemercier et al., 2000; Lu et al., 2000a; Lu et al., 2000b; Miska
et al., 1999; Sparrow et al., 1999; Zhang et al., 2001). Besides MEF2, class II HDACs
have been shown to associate with and repress the transcriptional activity of SRF,
GATA, NFAT and myocardin, each of which have been shown to regulate cardiac
hypertrophy (Frey and Olson, 2003).
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However, chemical HDAC inhibitors including trichostatin A (TSA), actually
prevent cardiac hypertrophy, leading to the conclusion that distinct HDACs play
positive or negative roles in the control of cardiomyocyte hypertrophy (Antos et al.,
2003; Kong et al., 2006). Consistent with this idea, HDAC2, a class I HDAC is
important for inducing hypertrophy in homeodomain only protein (HOP) transgenic
mice (Kook et al., 2003). Recently we have shown that global loss of HDAC2 results
in partial perinatal lethality due to cardiac developmental defects that include
enhanced cardiac myocyte proliferation. HDAC2 deficient mice were resistant to
cardiac hypertrophy when exposed to hypertrophic stimuli (Trivedi et al., 2007).
Resistance to hypertrophy was associated with increased expression of Inpp5f
resulting in constitutive activation of Gsk3β via inactivation of Akt and Pdk1. While
transgenic overexpression of HDAC2 in the heart reactivated fetal genes and induced
cardiac hypertrophy. Inpp5f was significantly downregulated in HDAC2 transgenic
heart (Trivedi et al., 2007).

1.7 GATA4 in heart development

In the later chapter of my thesis, I will describe some interesting HDAC2
knockout mice phenotypes which are related to GATA4 activity. The GATA family
of transcription factors, GATA1-6, are known to be critical for embryonic
development, cell growth, and differentiation (Viger et al., 2008). GATA transcription
factors are defined by an evolutionarily conserved DNA binding domain consisting of
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two zinc finger motifs that recognize the consensus-binding site WGATAR (Ko and
Engel, 1993; Merika and Orkin, 1993). The GATA family can be separated into two
subgroups based on spatial and temporal expression patterns. GATA1-3 are
predominantly expressed in hematopoietic cell lineages and are essential for erythroid
and megakaryocyte differentiation, the proliferation of hematopoietic stem cells, and
the development of T lymphocytes (Weiss and Orkin, 1995). In contrast, GATA4-6
are expressed in several mesoderm and endoderm derived tissues such as the heart,
gut and gonad (Charron and Nemer, 1999; Molkentin, 2000). GATA4 is one of the
earliest genes expressed by specified cardiac precursors at the cardiac crescent stage
of mouse development (Arceci et al., 1993; Kelley et al., 1993) and it has been
extensively characterized as an essential regulator of cardiac development and
differentiation, as well as in regulating survival and hypertrophic growth of the adult
heart (Oka et al., 2007). GATA4 regulates the expression of genes that are important
for cardiac contraction as well as the expression of other cardiac transcription factor
genes, such as Mef2c, Hand2, and Nkx2-5 (Dodou et al., 2004; Lien et al., 1999;
McFadden et al., 2000). Global loss of Gata4 in mice causes embryonic lethality at
E9.5 as a result of severe defects in the extra-embryonic endoderm and aberrant heart
and foregut morphogenesis (Kuo et al., 1997; Molkentin et al., 1997). Clinical studies
have indicated a role in human congenital heart defects (CHD) (Garg et al., 2003;
Pehlivan et al., 1999). Studies involving tissue-specific loss of Gata4 in murine
cardiac myocytes have demonstrated a critical role for Gata4 in embryonic myocyte
proliferation. Conditional inactivation of Gata4 using Nkx2-5 Cre resulted in
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embryonic lethality around E11.5, with decreased cardiomyocyte proliferation and
major defects in the development of the right ventricle (Zeisberg et al., 2005). Mice
lacking Gata4 in the anterior heart field (AHF), for example, die by E13.5 due to
significant right ventricular and interventricular septal myocyte proliferation defects.
Gata4-null cardiomyocytes show down-regulation of a wide array of cell cycle
associated genes, some of which are direct transcriptional targets of Gata4, including
cyclinD2 and cdk4 (Rojas et al., 2008).

1.8 GATA4 post-translational modification and activity

GATA4 activity is modulated in response to a number of intracellular signaling
pathways, and GATA4 protein is subject to post-translational modifications including
phosphorylation, acetylation and sumoylation (Kawamura et al., 2005; Liang et al.,
2001b; Wang et al., 2004). S105 phosphorylation by MEK1-ERK1/2 signaling
enhances Gata4 DNA binding and transcription activation in cardiomyocytes (Kitta et
al., 2003; Liang et al., 2001b). Gata4 is also activated by S261 phosphorylation via
the cAMP/Protein Kinase signaling pathway in gonadal cells (Tremblay and Viger,
2003). Sumoylation is required for Gata4 to gain the ability to activate endogenous
cardiac-specific genes (Wang et al., 2004). The histone acetyl transferase p300 is able
to acetylate Lys311, 318, 320, and 322 of Gata4, resulting in enhanced DNA binding
and transcriptional activity (Takaya et al., 2008). In transgenic mice, p300 overexpression in the heart induces Gata4 acetylation and cardiac hypertrophy (Miyamoto
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et al., 2006; Yanazume et al., 2003a). Interestingly, p300 null mice die at E9.5
exhibiting defects in proliferation and cardiac development (Yao et al., 1998).
Mechanisms for Gata4 deacetylation have, to our knowledge, not been previously
described.
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Table 1.1: The role of phosphatases in physiology and pathology in human and
mice

Gene

Function

Substrate(s)

Human disease

Mice phenotype

PTEN

3-ptase

PtdIns(3,4)P2
,
PtdIns(3,4,5)
P3

Cowden disease,
Lhermitte-Duclos
disease, Bannayan–
Riley–Ruvalcaba
syndrome, Cancer

Embryonic lethality of
PTEN -/-.
Tumorigenesis in
PTEN +/-.

SHIP

5-ptase

PtdIns(3,4,5)
P3

Acute Myelogenous

Myeloproliferative
phenotype with
progressive
splenomegaly,
massive myeloid
infiltration of the
lungs, shortened
lifespan of knockout
mice. Severe
osteoporotic
phenotype.
highly resistant to
weight gain when
placed on a high-fat
diet

Leukemia

SHIP2

5-ptase

PtdIns(3,4,5)
P3

Type 2 diabetes

Synapt
ojanin
1

5-ptase

PtdIns(4,5)P2
,
PtdIns(3,4,5)
P3

Bipolar disorder

die shortly after birth
due to neurological
defects

Synapt
ojanin
2

5-ptase

N/A

N/A

Inpp5f

5-ptase

PtdIns(4,5)P2
,
PtdIns(3,4,5)
P3
PtdIns(4,5)P2
,
PtdIns(3,4,5)
P3

N/A

Cardiac specific KO is
sensitive to
hypertrophic stimuli

Reference
s
(Leslie
and
Downes,
2002;
Pendaries
et al.,
2003
(Takeshita
et al.,
2002)
Helgason
et al.,
1998; Liu
et al.,
1998

Grempler
et al.,
2007;
Sleeman
et al.,
2005
Cremona
et al.,
1999;
Saito et
al., 2001;
Stopkova
et al.,
2004

Zhu et al.,
2009
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Table 1.2: Gene-targeted and transgenic models with altered PI3K/Akt signaling
in the heart
Genotype
Whole-body p110α KO
Cardiac-specific
CAPI3Kα
Cardiac specific DNPI3Kα

Phenotype
E9.5-E10.5 lethality
Increased
heart
cardiomyocyte size
Reduced
heart
cardiomyocyte size

Whole body PDK1 KO
Cardiac-specific PDK1

E9.5 lethality
Cardiomyopathy, reduced
cardiomyocyte
size,
increased sensitivity to
hypoxia,
increased
cardiomyocyte apoptosis
Growth
retardation,
normal glucose tolerance,
defective in physiological
hypertrophy
Insulin resistance, mild
growth retardation, normal
cardiac growth
Reduced brain size

Whole body Akt1 KO

Whole body Akt2 KO

Whole body Akt3 KO

and
and

References
Bi et al., 1999
Crackower et al., 2002;
Shioi et al., 2000
Crackower et al., 2002;
McMullen et al., 2003;
Shioi et al., 2000
Lawlor et al., 2002
Ito et al., 2009; Mora et
al., 2003

Chen et al., 2001; Cho et
al., 2001b; DeBosch et al.,
2006

Cho et al., 2001a; Garofalo
et al., 2003; DeBosch et
al., 2006a
Easton et al., 2005;
Tschopp et al., 2005
hypertrophy, Matsui et al., 2002;
myocardial Shiojima et al., 2005

Cardiac-specific CA-Akt1 Cardiac
(myr-Akt1)
normal
contractility
Cardiac-specific CA-Akt1 Cardiac
hypertrophy,
(Akt1 T308D/S473D)
reduced
myocardial
contractility
Cardiac-specific CA-Akt1 Cardiac
hypertrophy,
(Akt1 E40K)
enhanced
myocardial
contractility
Cardiac-specific KD-Akt1 attenuated the CA-PI3K(Akt1 K179M)
induced overgrowth of the
heart, normal myocardial
contractility
Cardiac-specific CA-Akt3 Cardiac
hypertrophy,
(myr-Akt1)
reduced
myocardial
contractility
Whole body Gsk3β KO
E16.5 lethality
Cardiac-specific Gsk3β
Reduced
maturational
growth of the heart
Cardiac-specific
CA Impaired
hypertrophic
Gsk3β (Gsk3β S9A)
responses

Shioi et al., 2002

Condorelli et al., 2002;
Kim et al., 2003
Shioi et al., 2002

Taniyama et al., 2005

Hoeflich et al., 2000
Michael et al., 2004
Antos et al., 2002
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Cardiac-specific inducible
Gsk3β (Gsk3β S9A)
Cardiac-specific
DN
Gsk3β (K85M/K86I)
Whole body knockin of
Gsk3β (Gsk3β S9A)
Cardiac-specific
CAmTOR
Cardiac-specific
KDmTOR

Reversal of pre-existing Sanbe et al., 2003
hypertrohpy
Cardiac hypertrophy with Hirotani et al., 2007
improved contractility
Reduced hypertrophy
Matsuda et al., 2008

Normal
response
to
hypertrophic stimuli
Normal
response
to
hypertrophic
stimuli,
reduced function
Muscle-specific PTEN KO Increased
heart
and
cardiomyocyte
size;
reduced
myocardial
contractility

Shen et al., 2008
Shen et al., 2008

Crackower et al., 2002,
Oudit et al., 2008
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Figure 1.1: Overview of the PI3K/Akt pathway.
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Figure 1.1: Overview of the PI3K/Akt pathway.
Upon activation, PI3K translocates to the cell membrane, converting PIP2 to PIP3.
The PH domain of both Akt and its activator PDK1 associate with PIP3 allowing
PDK1 to activate Akt. Activation of Akt then leads to activation of mTOR, a central
regulator of protein synthesis. Akt also phosphorylates and inhibits a kinase, Gsk3β.
Since Gsk3β inhibits protein translation and a number of transcription factors believed
to play roles in the induction of the hypertrophic program of gene expression,
inhibition of Gsk3β promotes both protein synthesis and gene transcription.
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Chapter 2 Inpp5f is a Polyphosphoinositide Phosphatase that
Regulates Cardiac Hypertrophic Responsiveness

Significant portions of this chapter have been published in Circulation Research (Zhu
et al., 2009).

2.1 Summary

Cardiac hypertrophy occurs in response to a variety of extrinsic and intrinsic
stimuli that impose increased biomechanical stress. The PI3K/Akt pathway has
previously been strongly associated with hypertrophic signaling in the heart, and with
the control of cell size in multiple contexts. This pathway is tightly regulated by many
factors, including a host of kinases and phosphatases that function at multiple steps in
the signaling cascade. For example, the PTEN tumor suppressor protein is a
phosphoinositide 3-phosphatase that, by metabolizing PtdIns(3,4,5)P3, acts in direct
antagonism to growth factor stimulated PI3K. Inhibition of PTEN leads to
cardiomyocyte hypertrophy.

Here, I characterize another polyphoinositide

phosphatase, inositol polyphosphate-5-phosphatase F (Inpp5f), which has recently
been implicated in regulation of cardiac hypertrophy. Like PTEN, this phosphatase
can degrade PtdIns(3,4,5)P3 and thus modulates the PI3K/Akt pathway. Inpp5f
knockout mice have augmented hypertrophy and reactivation of the fetal gene
program in response to stress when compared to wild type littermates. Furthermore,
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cardiac over-expression of Inpp5f in transgenic mice reduces hypertrophic
responsiveness.

These results suggest that Inpp5f is a functionally important

endogenous modulator of cardiac myocyte size and of the cardiac response to stress.

2.2 Introduction

Cardiovascular disease remains the number one cause of mortality in the
Western world, with heart failure representing the fastest growing subclass over the
past decade (Heineke and Molkentin, 2006). In many cases, cardiac hypertrophy
precedes cardiac dilation and heart failure. Cardiac hypertrophy can occur in response
to normal physiological stimuli or may be maladaptive leading to cardiac dilatation
and congestive heart failure. However, the cellular mechanisms that regulate the
hypertrophic response to agonists or to stretch remain poorly understood, and the
transition from hypertrophy to failure is also ill-defined. On the other hand, evidence
accumulating over the last few decades confirms that intercellular signaling pathways
and gene expression are fundamentally altered in states of hypertrophy and failure and
a thorough understanding of these changes will provide therapeutic targets (Dorn and
Force, 2005).

Recently, we showed that Hdac2 deficient mice are resistant to cardiac
hypertrophy when exposed to hypertrophic stimuli (Trivedi et al., 2007). Resistance to
hypertrophy in Hdac2-/- mice is associated with increased expression of the gene
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encoding inositol polyphosphate-5-phosphatase f (Inpp5f) and constitutive activation
of Gsk3β via inactivation of Akt and Pdk1. Conversely, transgenic over-expression of
Hdac2 in the heart reactivates fetal genes and induces cardiac hypertrophy. In these
transgenic hearts, Inpp5f is significantly down-regulated, Akt is activated, and Gsk3ß
is inactive (Trivedi et al., 2007). Further studies suggest that Hdac2 is a direct
regulator of Inpp5f (Trivedi et al., 2007). Thus, I hypothesized that Inpp5f might
functionally contribute to cardiac regulation of the Akt/Gsk3β pathway in response to
stress.

Inpp5f is one of several polyphosphoinositide phosphatases that have been
identified and partially characterized (Astle et al., 2007). Prior work demonstrates that
Inpp5f can degrade both phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2, PIP2)
and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3, PIP3) by removing the
5’ phosphate from the inositol ring(Minagawa et al., 2001). Although the PIP3 3’
phosphatase PTEN has previously been shown to regulate cardiac myocyte
hypertrophy and Akt signaling in the heart (Crackower et al., 2002; Oudit et al., 2004),
a functional role for a PIP3 5’ phosphatase in the heart has been less clear. However,
in various non-cardiac model systems, both 3’ and 5’ inositol phosphatases are
important regulators of PIP3 activity and downstream signaling. For example, the
SH2 domain-containing inositol 5'-phosphatase (SHIP) and PTEN both play
important roles to regulate PIP3 and Akt in immune cells (Kashiwada et al., 2007).

In order to determine the role of Inpp5f in the adult heart, I have created both
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gain- and loss-of-function models. Our results indicate that Inpp5f transgenic mice are
unable to reactivate fetal genes or to exhibit normal hypertrophic responses to
adrenergic agonists, while Inpp5f knockout mice exhibit augmented hypertrophy and
exaggerated reactivation of the fetal gene program under stress.

2.3 Results

2.3.1 Inpp5f regulates the PI3K/Akt pathway in vitro

Inpp5f removes the 5-phosphate from PIP3 (Minagawa et al., 2001) and thus I
predicted that Inpp5f is able to affect PI3K/Akt pathway activity. To test this, I
performed both transfection overexpression and siRNA knockdown experiments in
H9C2 cells, a cardiomyocyte cell line. Transfection of Inpp5f resulted in downregulation of pAkt and pGsk3β (Fig 2.1A). This effect was readily apparent despite an
estimated transfection efficiency of 50%. The decrease in Akt and Gsk3β
phosphorylation induced by Inpp5f overepression was reversed by co-transfection
with a constitutively activated Akt (caAkt) (Fig 2.1A), suggesting that Akt is
downstream of Inpp5f and is capable of regulating Gsk3β. Knockdown of Inpp5f in
H9C2 cells with siRNA resulted in enhanced Akt phosphorylation (Fig 2.1B). Thus,
Inpp5f is capable of modulating the Akt-Gsk3β pathway in vitro.
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2.3.2 Generation of Inpp5f antibody

To our knowledge, there are no commercially available Inpp5f antibodies. In
order to facilitate the study, I chose two epitope antigens (one from N-terminus and
the other from C-terminus of the protein) for antibody generation based on
hydrophilicity, orientation, flexibility and antigenecity analysis. I cloned these two
regions into pGEX-2T vectors separately. The plasmids were transformed into BL21
bacteria and glutathione S-transferase (GST) fusion proteins were extracted, purified
and confirmed by Coomassie blue staining (Fig 2.2A). The fusion proteins were then
sent to Cocalico Biologicals, Inc (Reamstown, PA) for injection into rabbit. By
computer prediction, the mouse Inpp5f protein is 129 kD. To confirm this prediction, I
made an N-terminal FLAG-tagged Inpp5f and a C-terminal MYC-tagged Inpp5f,
transfected into Cos7 cells and probed the cell proteins with either anti-FLAG
antibody or the anti-MYC antibody (Fig 2.2B). A predominant 130 kD band is
observed in Fig 2.2B. The rabbit anti-sera after the second injection was examined on
both FLAG-tagged Inpp5f containing vector and empty vector transfected cells. The
result shows that all four antibodies could recognize a band approximately 130 kD in
the Inpp5f expressing cells which was not detected in the control transfected cells (Fig
2.2C). Therefore, all 4 antibodies could recognize a protein of the predicted molecular
weight. Since the antibody #2086 gives less background, it was chosen for future
studies.
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2.3.3 Inactivation of Inpp5f

In order to produce mice lacking Inpp5f, we identified a gene-trap embryonic
stem (ES) cell line in which the endogenous Inpp5f locus has been disrupted within
intron 6, upstream of the exons encoding the catalytic phosphatase domain. This
gene-trap insertion is predicted to result in the production of a fusion protein
composed of the amino-terminal region of Inpp5f fused to ß-geo (Fig 2.3A).
Heterozygous gene-trap ES cells were injected into blastocysts to create chimeric
mice, which were bred to produce germ-line offspring. Resulting heterozygous mice
were inter-crossed to produce homozygous Inpp5f-/- offspring, which were born in
expected Mendelian ratios (Table 2.1), survived into adulthood and appeared healthy.
Genotype was confirmed by Southern blot (Fig 2.3B) and by PCR (Fig 2.3C). I
confirmed the lack of full length Inpp5f transcripts by real-time PCR using mRNA
from adult Inpp5f-/- and wild-type hearts (Fig 2.3D). Western blot using antibody
recognizing the C-terminus of Inpp5f demonstrated a lack of protein expression in the
knockout (Fig 2.3E). Thus, I conclude that I have generated a null allele for Inpp5f.

2.3.4 Further characterization of the Inpp5f genomic locus

Since the insertion is predicted to result in a fusion protein with the N-terminal
region of Inpp5f fused to β-geo, I sought to detect the β-gal activity in the knockouts.
I performed β-gal staining in E13.5 embryos as well as in several tissues of adult mice
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including the brain, liver and heart. However, I did not detect any β-gal staining (data
not shown). To exclude the possibility that the level of expression is too low to detect,
I utilized a sensitive β-galactosidase assay (Shaper et al., 1994; Young et al., 1993).In
the protein extracts from the Z/EG reporter mouse tail, which constitutively express
lacZ under the control of the CMV promoter (Novak et al., 2000), I was able to detect
large amounts of β-galactosidase activity. However, analysis of tissues from knockout
mice yielded results similar to those of the wildtypes (data not shown) and they are far
below the positive control.

I sought to further analyze the Inpp5f genomic locus to make sure that the βgeo cassette is inserted in the right locus and the mice are true knockouts. First of all,
I designed several primers to map the exact locus where the cassette is inserted (Fig
2.4A). As seen in Fig 2.4B, the cassette is somewhere between primer R3 and R4
within intron 6. I cloned the PCR product from FR3 in Fig 2.4A and sequencing
suggests that the insertion is at the 1752nd nucleotide within intron 6, which has 3291
nucleotides total. PCR from cDNA from the heart shows the existence of the fusion
transcript of the first 6 exons and β-geo (Fig 2.4C, D). Further in depth analysis of the
Inpp5f genomic locus affected by the gene-trap revealed that the insertion event was
accompanied by a loss of endogenous genomic sequence spanning exons 7-13 (Fig
2.5).

Thus, the affected allele cannot produce a full-length protein or one with

functional phosphatase activity.

There are several possibilities why the fusion

transcript is produced but no β-galactosidase activity is detected. Perhaps the fusion
protein is not stable. It is also possible that large deletion of gemonic DNA results in a
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loss of some important enhancer elements that are required for efficient tissue-specific
transcription.

2.3.5 Inpp5f null hearts appear normal

We examined cardiac histology, size and function in Inpp5f-/- and littermate
control mice. H&E staining of hearts was performed at E14.5, P0 and 2 months of age.
At these time points, we could not identify any differences and Inpp5f null mice
appear normal by gross and histological assessment (Fig 2.6A). We measured cardiac
weight in relation to total body weight to determine relative cardiac size. At both 2
and 9 months of age, there was no difference in heart to body weight ratio between
wild type and Inpp5f-/- littermates (Fig 2.6B, C).

In order to evaluate the functional impact of the loss of Inpp5f, we performed
echocardiography on Inpp5f-/- and wild type litter mates at 2 and 9 months (Table 2.2).
We did not observe any significant difference in the inter-ventricular septum (IVS),
left ventricular posterior wall (LVPW) and the left ventricular internal diameter (IVID)
measurements at either end-diastole or end-systole. Left ventricular (LV) ejection
fraction (EF) and fractional shortening (FS) also was not different between groups.
Thus, under basal conditions, Inpp5f-/- mice appear to have normal cardiac form and
function.
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2.3.6 Inpp5f regulates stress-induced hypertrophy

Next, we sought to determine if adult mice lacking Inpp5f would be more
susceptible to agonist-induced cardiac hypertrophy. Wild-type and Inpp5f-/- litter
mates at 2 months of age were treated with a constant infusion of saline or
isoproterenol (ISO) delivered by osmotic mini-pump for 14 days. Animals lacking
Inpp5f showed an increase in ISO-induced cardiac hypertrophy as measured by either
the heart to body weight ratio or the heart weight to tibia length ratio (Fig 2.7A). In
response to ISO, Inpp5f-/- heart also showed more potent reactivation of the fetal
program of gene expression than wild type litter mates; transcripts for Nppa (encoding
atrial natriuretic factor, ANF), Myh7 (encoding β-MHC) and Nppb (encoding BNP)
increased more dramatically in the knockout hearts (Fig 2.7B). Cellular hypertrophy,
as revealed by wheat germ agglutinin (WGA) staining followed by quantification, was
more pronounced in the Inpp5f-/- hearts compared to wild-type hearts after ISO (Fig
2.7C) (256.5 + 21.8 µm2 for Inpp5f

-/-

mice treated with ISO, n = 446 cells from 3

hearts; 194.8 + 6.8 µm2 for wild type mice treated with ISO, n = 514 from 3 hearts).
Patchy areas of fibrosis were more evident in ISO-treated Inpp5f-/- hearts when
compared to controls (Fig 2.7D) (Quantification of fibrotic area was 7.3% for Inpp5f /-

mice, 25 sections, three hearts; 1.8% for wild type mice, 27 sections, three hearts).

We also observed more apoptotic cells in the Inpp5f-/- hearts after ISO treatment
compared to wild type (0.37% of 16,804 cells from 4 Inpp5f-/- hearts, 0.24% of 21,558
cells from 5 wild type hearts, p = 0.01). Functional assessment by echocardiography
after 2 weeks of ISO treatment revealed relative preservation fractional shortening
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and ejection fraction, with thickening of the posterior wall in Inpp5f-/- animals at this
time point (Table 2.3).

Neonatal myocytes isolated from Inpp5f-/- and wild type littermates revealed
similar levels of Akt and Gsk3ß phosphorylation under basal conditions (Fig 2.7E).
Treatment with ISO resulted in increased phosphorylation of Akt and Gsk3β in
knockout cells when compared to controls (Fig. 2.7E), while no significant
differences in Erk activation were noted (data not shown). IGF-1 treatment of
myocytes revealed similar results (data not shown). Taken together, our data suggest
that cardiac myocytes lacking Inpp5f are sensitive to stress-induced cardiac
hypertrophy and activation of the Akt pathway.

2.3.7 PIP3 levels are altered in Inpp5f null mice

Although a prior report has indicated that Inpp5f exhibits 5-phosphatase activity
when PtdIns(3,4,5)P3 and PtdIns(4,5)P2 are used as substrates in vitro (Minagawa et
al., 2001), I sought to determine directly if loss of Inpp5f alters endogenous cardiac
PIP3 levels in vivo. Endogenous PtdIns(3,4,5)P3 levels are low, and I am unaware of
prior studies that directly measure levels of this important signaling molecule in vivo
in genetically engineered animals. Therefore, I took two approaches simultaneously.
First, I pursued collaboration with Dr Andrew Quong at the Thomas Jefferson
University to measure the PIP3/PIP2 levels in the lipid extraction from adult knockout,
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Tg and wildtype hearts by mass spectrometry. Our preliminary results (Fig 2.8A) with
wild type hearts suggest that accurate measurements would be possible though
significant optimization is required. The major problem is that signals are weak and
they don’t separate well enough from other signals. All the major signals turned out to
be

glycerophosphocholine,

sphingomyelin,

glycerophosphoethanolamide

and

glycerophosphatidic acids. As an alternative approach, I adapted an ELISA-based
sensitive assay that has been used for cultured cells and compared PIP3 levels in
control and Inpp5f-/- hearts before and after ligand stimulation intended to augment
PIP3 levels. Heart tissue from 4 mice age 3-5 weeks was combined for each condition,
and some samples were treated ex vivo with IGF-1, a potent activator of PI3K and
AKT in the heart. Our data shows that PIP3 levels in Inpp5f-/- mice are ~1.6 fold
greater than wild type littermates. However, upon IGF-1 stimulation, PIP3 levels in
the knockout hearts increased to 4.9 fold those of stimulated wild type littermates (Fig
2.8B). Thus, loss of Inpp5f sensitizes the heart to hypertrophic stimulation.

2.3.8 Cardiac-specific Inpp5f transgenic mice

I used the well-characterized α-myosin heavy chain (α-MHC) promoter to
direct cardiac-restricted expression of Inpp5f in transgenic mice (Fig 2.9A). I utilized
two distinct strategies. First, I generated Flag-tagged Inpp5f. However, epitope
tagging always has the possibility of affecting protein function. Therefore, I also
generated a transgenic construct in which I included an IRES-GFP sequence after the
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Inpp5f coding region. With this construct, I would be able to easily determine if the
transgene is specifically expressed in the heart (via GFP expression) and accurate
transgenic protein levels would be determined by the Inpp5f antibody I generated. 2
transgenic lines were generated for the Flag-tagged transgenic mice and 6 lines were
generated for the IRES-GFP transgenic mice in order to control for effects mediated
by sites of insertion. With both two strategies, I was able to confirm the germline
transmission of the transgene by PCR (Fig 2.9B).

For the Flag-tagged Inpp5f

construct, I was also able to determine the transgene mRNA level by real-time PCR
(data not shown) and verify the transgenic expression by Western blotting (Fig 2.9C)
which revealed similar levels of protein expression in the two independent lines.
However, for the IRES-GFP construct, Real-time PCR for Inpp5f gene didn’t show
any increase in the mRNA level (data not shown) and Western Blot for GFP didn’t
show detectable expression either (Fig 2.9D), which may be due to gene silencing,
recombination, etc. I analyzed the phenotypes using the two lines of Flag-Inpp5f
transgenic mice.

2.3.9 Inpp5f transgenic mice are resistant to stress-induced hypertrophy

Adult Inpp5f transgenic mice appeared healthy. Heart to body weight ratios of
transgenic and wild type littermates were not significantly different at P60 (Fig
2.10A). Control and Inpp5f transgenic littermates at 2 months of age were treated
with a constant infusion of saline or ISO for 14 days. As predicted, wild-type mice
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exhibited cardiac hypertrophy, as revealed by an increase in both the heart to body
weight ratio and the heart weight to tibia length ratio (Fig 2.10A). Hypertrophy of
Inpp5f transgenic mice in response to ISO was significantly blunted (Fig 2.10A).
Likewise, reactivation of the fetal gene program that accompanied hypertrophy in
control animals was markedly attenuated in transgenic animals (Fig 2.10B). After
treatment with ISO, we noted activation of the Akt pathway with enhanced
phosphorylation of Akt and Gsk3ß in the control hearts (Fig 2.10C). However, ISOinduced increases in phospho-Akt and phospho-Gsk3ß were blunted in transgenic
hearts.

2.3.10 Inpp5f has a Sac domain and it has the conserved catalytic motifs

As discussed in the introduction, Inpp5f has a Sac domain, which is
approximately 400 amino acid residue in length and defined by seven conserved
motifs which appear to define the catalytic and regulatory regions of the
phosphatase(Hughes

et

al.,

2000).

The

highly

conserved

sequence

RXNCXDCLDRTN in the sixth motif is proposed to be the catalytic core of the SAC
domain phosphatases. The SAC domain of the yeast synaptojanin-like protein Inp51p
does not exhibit phosphatase activity, and the cysteine, arginine and threonine/serine
residue are absent from CX5R(T/S) motif of this protein. In order to examine whether
this novel protein also has these seven conserved motifs and the active catalytic core,
I downloaded the sac1p and the Inp51p protein sequences in S.cerevisiea from NCBI,
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and aligned these sequences together with the human and mouse Inpp5f sequences by
CLUSTALW(Chenna et al., 2003). Sac1p exhibits phosphatase activity and actually it
is the first protein in which the Sac domain is identified(Guo et al., 1999; Hughes et
al., 2000). I identified seven highly conserved motifs and the sixth conserved region
of Inpp5f in both mouse and human has the highly conserved CX5R(T/S) motif (Fig
2.11).

2.3.11 Interaction of Inpp5f with PDK1

I have showed that one mechanism for Inpp5f to regulate PI3K/Akt pathway is
by dephosphorylating PIP3. As an attempt to look for other mechanisms how Inpp5f
might affect this pathway, I identified a potential PDK1 interaction domain. I
hypothesized that Inpp5f would interact with PDK1 and down-regulate its activity. I
tested the interaction by co-transfecting Flag tagged Inpp5f and Myc tagged PDK1
and performing co-immunoprecipitation. As shown in Fig 2.12, I didn’t detect any
interaction between Inpp5f and PDK1. Some possibilities exist. First, PDK1 might
interact with Inpp5f only under certain conditions, such as activation of the PI3K/Akt
pathway. Second, some post-translational modifications might be required for the
interaction, such as phosphorylation, acetylation, etc. Further experiment could be
performed to detect the interaction under other conditions.
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2.3.12 Genetic epistasis analysis

We have demonstrated that Hdac2 promotes cardiac hypertrophy and Inpp5f is
up-regulated in Hdac2 knockout hearts, both during late gestation and in the adult
while it is down-regulated in Hdac2 transgenic mice that over-express Hdac2 in the
heart. Hdac2 can deacetylate histones at the Inpp5f upstream genomic region,
consistent with direct regulation (Trivedi et al., 2007). My data also suggests that
Inpp5f transgenic mice were unable to reactivate fetal genes or to exhibit normal
hypertrophic responses and the transgenic hearts have decreased levels of phosphoAKT and phospho-GSK3β. In contrast, Inpp5f knockout mice have augmented
hypertrophy associated with reactivation of the fetal gene program. However, it
remains unclear to what extent Hdac2 regulates hypertrophy via Inpp5f as opposed to
other, yet to be identified, mechanisms. To examine this, I crossed Hdac2+/- mice to
Inpp5f-/- mice, and the resulting Hdac2+/-, Inpp5f+/- offspring were intercrossed to
produce Hdac2-/-, Inpp5f-/- animals. I expect that the absence of Inpp5f will restore
hypertrophic responsiveness in Hdac2 knockout mice. Table 2.4 shows the genotyping
result I have obtained so far. I have not detected any double nulls, which could be
either due to limited numbers or embryonic lethality. More genotyping and further
analysis are needed to investigate this question.

Similarly, my work has also supported a role of Akt in the phenotypes I
observed in Inpp5f knockout and transgenic mice. Deletion of Inpp5f leads to higher
level of phospho-Akt and reactivation of fetal gene programs, which results in
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sensitivity to hypertrophic stimuli. To further test the genetic epstasis of this pathway,
I crossed Akt+/- mice, a general gift from Dr. Morris J. Birnbaum, to Inpp5f-/- mice,
and then I crossed the resulting Akt+/-, Inpp5f+/- offspring to produce Akt-/-, Inpp5f/- animals. Table 2.5 displays the genotyping result. Likewise, more numbers are
necessary before firm conclusions can be made.

2.4 Discussion

In this study, we investigated the effects of gain- and loss-of-function of Inpp5f.
Our results suggest that Inpp5f modulates stress-induced hypertrophic responsiveness
in the heart. Under basal conditions, Inpp5f knockout and transgenic mice appear
normal, with preserved cardiac structure and function. However, in the setting of
adrenergic stimulation produced by infusion of isoproterenol, Inpp5f-/- animals had
elevated level of PIP3 and showed accentuated hypertrophy as measured by heart size,
myocyte size and gene expression.

Isolated myocytes lacking Inpp5f were

hypersensitive to ISO and IGF-1 as reflected by accentuated activation of Akt
compared to control myocytes. Conversely, Inpp5f transgenic mice were relatively
resistant to hypertrophic stimulation.

Inpp5f encodes a 5’ PIP3 phosphatase that is predicted to reduce PIP3 levels
and subsequent activation of Akt and downstream signals. Our biochemical findings
in Inpp5f transgenic and knockout hearts are consistent with this mode of action. The
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Akt signaling network in the adult heart has been extensively examined and has been
shown to contribute to both adaptive (physiologic) and maladaptive (pathologic)
hypertrophy(Oudit et al., 2004). Akt1-/- mice have a 20% reduction in body size, with
a concomitant reduction in heart size(Cho et al., 2001b) and they are defective in
exercise-induced cardiac hypertrophy(DeBosch et al., 2006b). Cardiac specific overexpression of constitutively active or dominant negative forms of Akt lead to larger or
smaller hearts respectively(Condorelli et al., 2002; Matsui et al., 2002; Shioi et al.,
2002). Enhanced Akt activity is associated with increased p70S6 kinase activity and
increased phospho-Gsk3β(Matsui et al., 2002; Shioi et al., 2002). Cardiac-specific
over-expression of constitutively active Gsk3β is associated with reduced agonist and
pressure-overload hypertrophy confirming that Gsk3β functions as a negative
regulator of hypertrophy in vivo(Zhang et al., 2002). Thus, the alterations in Akt and
Gsk3β phosphorylation that we observed in Inpp5f knockout and transgenic hearts are
consistent with a model in which Inpp5f regulates PIP3 levels, Akt and Gsk3β activity
and subsequent hypertrophic responsiveness.

The inositol polyphosphate 5-phosphatases are a large family of enzymes
comprising at least 10 mammalian and 4 yeast members(Astle et al., 2006). Inpp5f
has a Sac phosphatase domain which exhibits phosphatidylinositol polyphosphate
phosphatase activity(Minagawa et al., 2001). The Sac domain is approximately 400
amino acid residue in length and defined by seven conserved motifs which appear to
define the catalytic and regulatory regions of the phosphatase(Hughes et al., 2000).
The highly conserved sequence RXNCXDCLDRTN in the sixth motif is proposed to
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be the catalytic core of the SAC domain phosphatases. The CX5R(T/S) motif within
this sequence is also found in a number of metal-independent protein phosphatases
and inositol polyphosphate phosphatases and is known to be a phosphatase catalytic
site(Guo et al., 1999; Hughes et al., 2000). Interestingly, the SAC domain of the yeast
synaptojanin-like protein Inp51p does not exhibit phosphatase activity, and the
cysteine, arginine and threonine/serine residue are absent from CX5R(T/S) motif of
this protein, being replaced by alanine, lysine and proline respectively. Furthermore,
mutations of the first conserved aspartate residue in the RXNCXDCLDRTN sequence
as seen in the yeast sac1-8 and sac1-22 mutant alleles were demonstrated to inactivate
the Sac1p functions(Hughes et al., 2000; Kearns et al., 1997; Zhong and Ye, 2003).

Some 5-phosphatases, such as the Src homology 2 (SH2) domain-containing
inositol polyphosphophate 5-phosphatases 1 and 2 (Ship and Ship2) have been
extensively characterized(Backers et al., 2003; Dyson et al., 2005; Harris et al., 2008;
Krystal et al., 1999; Rohrschneider et al., 2000). Ship is expressed predominantly in
hematopoietic cells where it is an important negative regulator of cytokine signaling.
Ship-/- mice have a short life span associated with massive myeloid cell infiltration of
the lungs and numerous hematopoietic abnormalities(Helgason et al., 1998; Liu et al.,
1998). Ship2 is more widely expressed, with high expression in brain, skeletal muscle
and heart(Astle et al., 2006). It plays an important role in insulin signaling and obesity
regulation(Grempler et al., 2007; Sleeman et al., 2005). Ship2 has been reported to be
a negative regulator of Akt activation. Although loss of Ship2 is not sufficient to
activate Akt, the absence of Ship2 allows for greater activity upon Akt
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stimulation(Rommel et al., 2001; Wada et al., 2001). These findings are reminiscent
of our results with regard to Inpp5f-mediated regulation of basal and agonist-induced
activation of Akt in the heart.

Although PTEN and the 5-phosphatases can all degrade PIP3, the degradation
products are distinct. Whereas PTEN converts PIP3 to PI(4,5)P2, the 5-phosphatases
convert PIP3 to PI(3,4)P2, which can function as a second messenger (Dowler et al.,
2000). Therefore, the production of PI(3,4)P2 from PIP3 by Inpp5f and Ship
phosphatases may function in part via active signaling, whereas PTEN action appears
to be mediated through loss of active PIP3 signaling(Leslie and Downes, 2002). For
example, PI(3,4)P2 has been shown to activate reactive oxygen species (ROS)(Brown
et al., 2003) and the generation of ROS is a process that is increasingly recognized as
an

important

contributor

to

depressed

cardiac

function

and

maladaptive

remodelling(Takimoto and Kass, 2007). Thus, this process could also contribute to the
phenotype we observed. Moreover, PI(3,4)P2 activity has been shown to correlate
with Akt phosphorylation and activity(Ma et al., 2008). Inpp5f can also
dephosphorylate PI(4,5)P2(Minagawa et al., 2001), and depletion of PI(4,5)P2 may
contribute to cardiomyocyte apoptosis and subsequent heart failure(Halstead et al.,
2005). Thus, regulation of PI(4,5)P2 levels may contribute to the mechanism by
which Inpp5f regulates hypertrophy.

Under the sedentary conditions, we found that Inpp5f null mice have slightly
higher level of cardiac PIP3, though phospho-Akt and phospho-Gsk3β are unaltered
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and the mice do not show abnormal hypertrophy. However, upon IGF-1 stimulation,
PIP3 levels in the knockout mice increase dramatically and they are more sensitive to
hypertrophic stimuli. Hence, unlike PTEN, which alters the basal level of PIP3(Leslie
and Downes, 2002), Inpp5f appears to modulate PIP3 levels primarily upon agonistinduced stimulation.

Our prior studies have suggested that Inpp5f is repressed at the transcriptional
level by Hdac2. Inpp5f transcripts are elevated in Hdac2 knockout hearts and are
diminished by over-expression of Hdac2 in the heart. siRNA-mediated knockdown of
Hdac2 or chemical Hdac inhibition in H9C2 myocytes results in increased levels of
Inpp5f and decreased phosphorylation of Akt and Gsk3ß. Although Hdac2 may
modulate cardiac myocyte size and hypertrophic signaling via multiple pathways, our
analysis of Inpp5f knockout and transgenic mice are consistent with a functional
relationship between Hdac2 and Inpp5f in the setting of hypertrophic stimulation.

Taken together, the work presented here suggests that Inpp5f functions as a
negative regulator of cardiac hypertrophy and Akt signaling. Loss of Inpp5f sensitize
the heart’s response to hypertrophic stimuli by modulating PI(3,4,5)P3 levels.

2.5 Materials and methods
Inpp5f-/- knockout mice. An Inpp5f gene-trap ES clone was obtained from
BayGenomics (now the International Gene Trap Consortium, ES clone no. XL0571).
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The Inpp5f genomic locus is interrupted by insertion of the pGT01xf vector, which
integrated into intron 6. Chimeric mice were produced by blastocyst injection
according to standard protocols. Mice were genotyped by Southern blotting analysis
of ScaI digested genomic DNA. Inpp5f+/+ and Inpp5f–/– mice were subsequently
genotyped by PCR using:
Wt F: 5' -AAAGCAGGTTGTGAAGTGGAGCTG- 3',
Wt R: 5' -TGCTCTTGTCATCATCCGAGGACT- 3',
Mut F: 5' -ATATTGAAACCCACGGCATGGTGC- 3' and
Mut R: 5' -TTTGATGGACCATTTCGGCACAGC- 3' primers. The mutant mice have
one band at 323 bp, and the wild type mice have one band at 1039 bp.
The loss of Inpp5f was confirmed by qRT-PCR using
5' -ACAGGAGAAAGGAAGTTGGCAGGA -3' and
5' -AGCTTCATGCTCCTTCTCCTTGGT -3' primers, and by Western blot analysis
using a rabbit polyclonal antibody targeted to the C terminus of Inpp5f (generated by
our lab, see below).

Inpp5f-transgenic mice. A cDNA encoding human Flag-tagged Inpp5f was cloned
into an expression plasmid containing the Myh6 (encoding α-Mhc) promoter(Heine et
al., 2005), and transgenic mice were generated by standard techniques. Genotyping
was

performed

by

PCR

analysis

TCTTCCAAGCCAAGGACCACTACA-

of

genomic
3'

and

DNA

using
5'

5'-

TCTGCACGGAATTGGTCAGGTCAT- 3', and cardiac specific expression of Inpp5f
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was revealed by qRT-PCR using 5' -ACAGGAGAAAGGAAGTTAGCAGGA- 3' and
5' -AGCTTCATGTTCTTTCTCCTTGGT- 3' primers and Western blot analysis using
antibodies to Flag (Sigma, F3165) or Inpp5f (generated by our lab, see below).

Inpp5f antibody generation. GST-Inpp5f fusion protein was expressed in bacteria,
purified by standard techniques and used to immunize rabbits (Cocalico Biologicals
Inc). A region of mouse Inpp5f cDNA encoding 61 C-terminal amino acids was
amplified by PCR using primers 5'-CGGACTGGCTTCACAAAGCCCA-3', 5'AGGAGGCGTCTGTCCCATTGGT-3' and cloned into the pGEX-2T vector. The
GST fusion protein was expressed in BL21 bacteria, extracted and purified using
Glutathione Sepharose 4B (GE Healthcare) according to the manufacturer’s
instructions. Purified protein was used to immunize rabbits (Cocalico Biologicals
Inc).

Western blotting. Tissue lysates were prepared in lysis buffer consisting of 20 mM
Tris HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100,
1 µg/ml leupeptin, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM βglycerophosphate. 1mM PMSF was added before use. Samples were separated by
SDS-PAGE and transferred to PVDF membranes. We used antibodies to Gapdh
(1:5,000 dilution, Chemicon, MAB374), phospho-Gsk3β (Ser 9), total Gsk3β,
phospho-Akt (Ser 473), total Akt (1:1000 dilution, Cell Signaling, #9336, #9315,
#4058, #9272). Primary antibody binding was visualized by using the Western Breeze
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Kit (Invitrogen) according to the manufacturer’s instructions. Inpp5f antibody was
purified by Melon Gel IgG Spin Purification kit (Thermo Scientific) and then diluted
1:100 in 5% milk.

Treatment with isoproterenol. Isoproterenol (Sigma, I5627) was delivered by
implanting a micro-osmotic pump (Alzet, Durect; model 1002) subcutaneously under
pentobarbital anesthesia. ISO (30 mg/kg/d) or vehicle (Dulbecco’s phosphate buffered
saline, Gibco) was infused subcutaneously for 14 days as described previously13.

Histology: Adult mouse hearts were collected in ice-cold PBS, fixed overnight in 4%
paraformaldehyde at 4°C, washed with PBS, and dehydrated through an ethanol series
prior to paraffin embedding. Masson’s Trichrome (to reveal fibrosis) and H&E stains
were performed according to standard protocols.

β-galactosidase assay: β-galactosidase activity is measured by Galacto-Light (Tropix,
BL100G). Activity was expressed as units/mg protein.

Apoptosis analysis. Apoptosis was measured by TUNEL assay (Roche, 1684795).
The total number of cells was quantified using ImageJ software.

Quantitative real time PCR. Total RNA was isolated from dissected mouse hearts
using Trizol (Invitrogen). RNA was reverse-transcribed using random hexamers and

51

the Superscript First Strand Synthesis Kit (Invitrogen). Gene expression was then
evaluated by qRT-PCR (ABI PRISM 7900) using the SYBR Green (Applied
Biosystems). Signals were normalized to their corresponding Gapdh controls and the
ratios expressed as fold changes compared to wild-type. PCR conditions and primer
set sequences are available upon request.

IGF-1 treatment. Hearts from one-month old mice were minced and incubated with
100nM Insulin like growth factor 1 (IGF-1) (Sigma, I8779) for 30 min at 37oC
followed by lipid extraction.

PIP3 ELISA. Mouse heart tissue was pulverized under liquid nitrogen using a mortar
and pestle, followed by lipid extraction and ELISA assays as per manufacture’s
instruction (Echelon Biosciences Inc, K-2500). ELISA measurements were performed
in triplicate after combining tissue from 4 hearts. .

Inpp5f-/- knockout mice. Inpp5f+/+ and Inpp5f–/– mice were genotyped by PCR using:
Wt F: 5' -AAAGCAGGTTGTGAAGTGGAGCTG- 3',
Wt R: 5' -TGCTCTTGTCATCATCCGAGGACT- 3',
Mut F: 5' -ATATTGAAACCCACGGCATGGTGC- 3' and
Mut R: 5' -TTTGATGGACCATTTCGGCACAGC- 3' primers.
The mutant mice have one band at 323 bp, and the wild type mice have one band at
1039 bp.
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The loss of Inpp5f was confirmed by qRT-PCR using
5' -ACAGGAGAAAGGAAGTTGGCAGGA -3' and
5' -AGCTTCATGCTCCTTCTCCTTGGT -3' primers.

Inpp5f-transgenic mice. Genotyping was performed by PCR analysis of genomic
DNA

using

5'-TCTTCCAAGCCAAGGACCACTACA-

3'

and

5'

-

TCTGCACGGAATTGGTCAGGTCAT- 3', and cardiac specific expression of Inpp5f
was revealed by qRT-PCR using 5' -ACAGGAGAAAGGAAGTTAGCAGGA- 3' and
5' -AGCTTCATGTTCTTTCTCCTTGGT- 3' primers.

Inpp5f antibody generation. The primers for amplifying mouse Inpp5f cDNA are 5'CGGACTGGCTTCACAAAGCCCA-3', 5'-AGGAGGCGTCTGTCCCATTGGT-3'.

Statistic analysis. All data are expressed as the mean ± SD. Student’s t test was used
to compare heart to body weight ratios and heart weight to tibia length ratios.
Probability values <0.05 were considered statistically significant.
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Table 2.1: Loss of Inpp5f does not lead to embryonic or perinatal lethality.

P0~P21

Genotype
(offspring of
heterozygous
crosses)
Inpp5f +/+

Expected

Observed

105

123

Inpp5f +/-

210

192

Inpp5f -/-

105

105

Total

420

420

χ2=4.629, 2 DOF, p=0.10

Reproduced from (Zhu et al., 2009).
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Table 2.2 Inpp5f-/- mice have normal cardiac function by echocardiography.
2 months
wild type Inpp5f KO
(n=3)

9 months
wild type Inpp5f KO
p Value

(n=3)

p Value
(n=4)

(n=4)

IVSd (mm)

0.69+0.06 0.66+0.03

ns

0.66+0.06 0.67+0.07

ns

IVSs (mm)

1.13+0.12 1.00+0.04

ns

0.96+0.10 1.02+0.09

ns

LVPWd (mm) 0.69+0.06 0.64+0.07

ns

0.65+0.03 0.70+0.06

ns

LVPWs (mm) 1.02+0.13 0.90+0.07

ns

0.95+0.14 1.04+0.07

ns

LVIDd (mm) 3.92+0.16 3.76+0.13

ns

4.13+0.22 4.13+0.48

ns

LVIDs (mm) 2.57+0.10 2.54+0.17

ns

2.98+0.12 2.92+0. 40

ns

LVEF (%)

64+2

60+4

ns

56+4

57+4

ns

LVFS (%)

34+1

31+3

ns

29+3

29+2

ns

ns: not significant

Reproduced from (Zhu et al., 2009). This data was produced in collaboration with
L.Yuan at the Physiology Core of the Cardiovascular Institute at the University of
Pennsylvania.
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Table 2.3: Echocardiography of wild type and Inpp5f-/- mice after 2 weeks of
ISO infusion.

2 months
wild type Inpp5f KO
(n=5)

p Value

(n=5)

IVSd (mm)

0.69+0.10 0.78+0.15

ns

IVSs (mm)

1.01+0.17 1.16+0.25

ns

LVPWd (mm) 0.65+0.06 0.74+0.06

0.04

LVPWs (mm) 0.98+0.13 0.98+0.16

ns

LVIDd (mm)

3.97+0.36 3.96+0.45

ns

LVIDs (mm)

2.80+0.45 2.76+0.60

ns

LVEF (%)

57+12

59+12

ns

LVFS (%)

30+8

31+8

ns

Reproduced from (Zhu et al., 2009).
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Table 2.4: Genotyping result from Hdac2+/-, Inpp5f+/- intercross (N=75).
Genotype

N

Hdac2 +/+ Inpp5f +/+

8

Hdac2 +/+ Inpp5f +/-

10

Hdac2 +/+ Inpp5f -/-

7

Hdac2 +/- Inpp5f +/+

9

Hdac2 +/- Inpp5f +/-

24

Hdac2 +/- Inpp5f -/-

11

Hdac2 -/- Inpp5f +/+

4

Hdac2 -/- Inpp5f +/-

2

Hdac2 -/- Inpp5f -/-

0
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Table 2.5: Genotyping result from Akt+/-, Inpp5f+/- intercross (N=86).
Genotype

N

Akt +/+ Inpp5f +/+

10

Akt +/+ Inpp5f +/-

13

Akt +/+ Inpp5f -/-

6

Akt +/- Inpp5f +/+

10

Akt +/- Inpp5f +/-

21

Akt +/- Inpp5f -/-

15

Akt -/- Inpp5f +/+

5

Akt -/- Inpp5f +/-

6

Akt -/- Inpp5f -/-

0
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Figure 2.1: Inpp5f regulates PI3K/Akt pathway in vitro.

Reproduced from (Trivedi et al., 2007).
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Figure 2.1: Inpp5f regulates PI3K/Akt pathway in vitro.
(A) Overexpression of Inpp5f in H9C2 cells resulted in decreased phosphorylation of
Gsk3β and Akt. Phosphorylated and total Gsk3β and Akt were measured by Western
Blot with or without transfection of Inpp5f and caAkt expression vectors. (B) H9C2
cells were treated with siRNA to knockdown Inpp5f, and total and phosphorylated
Akt levels were measured by Western Blot.
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Figure 2.2: Generation and confirmation of Inpp5f antibodies.
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Figure 2.2: Generation and confirmation of Inpp5f antibodies.
A. Coomassie blue staining of the GST fusion protein. Lane 1, maker; Lane 2,
unpurified protein; Lane 3, GST only; Lane 4, GST fused with epitope N; Lane 5,
GST fused with epitope C. B. Tranfection of Cos7 cells with epitope tagged plasmid
to determine the size of Inpp5f protein. Lane 1, control cell protein; Lane 2, FLAGtagged Inpp5f transfected cell protein; Lane 3, MYC-tagged Inpp5f transfected cell
protein. C. Examination of 4 sera on both Flag-tagged Inpp5f containing plasmid
(Lane 1, 3, 5, 7) and empty vector transfected cells (Lane 2, 4, 6, 8).
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Figure 2.3: Inactivation of Inpp5f.

Reproduced from (Zhu et al., 2009).
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Figure 2.3: Inactivation of Inpp5f.
(A) Schematic representation of Inpp5f protein (top) and gene structure. The wild
type and gene trap alleles are shown; exons are represented by black boxes. The sizes
of the expected restriction fragments recognized by the Southern probe (indicated) are
shown. (B) Southern blot of adult mice tail DNA resulting from a cross between
Inpp5f+/-heterozygotes. (C) PCR genotyping of offspring resulting from a cross
between Inpp5f +/-heterozygotes. (D) Real-time quantitative PCR of mRNA from adult
wild-type and Inpp5f-/- hearts shows the absence of Inpp5f mRNA in the knockout
hearts. (E) Western blot of wild-type and Inpp5f-/- adult heart tissue shows loss of
Inpp5f protein in mutant hearts.

64

Figure 2.4: Confirmation of genetrap insertion and existence of fusion mRNA.
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Figure 2.4: Confirmation of genetrap insertion and existence of fusion mRNA.
(A) Schematic of Inpp5f genomic DNA and the predicted genomic locus following
the genetrap cassette insertion. The primers for PCR are shown. (B) PCR results from
knockout and wildtype mice using 4 different reverse primers are shown. (C)
Schematic representation of the Inpp5f fusion mRNA transcript. The primers for the
Real-time PCR are shown. (D) Real-time RCR of mRNA from four individual
knockout mice and their wild type littermate controls using primers shown in (C).
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Figure 2.5: Examination of the endogenous Inpp5f genomic sequence.

Reproduced from (Zhu et al., 2009).
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Figure 2.5: Examination of the endogenous Inpp5f locus and the targeted locus.
Primers specific for each exon (4-20) were used to determine if the genomic sequence
corresponding to these exons was present in the wildtype and homozygous mutant
genome. PCR results show that exon 7 to 13 are deleted in the Inpp5f homozygous
mutant genome.
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Figure 2.6: Inpp5f -/- hearts appear normal.

Reproduced from (Zhu et al., 2009).
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Figure 2.6: Inpp5f -/- hearts appear normal.
(A) H&E-stained sections of wild-type and Inpp5f-/- hearts at E14.5, E16.5 and P65
(scale bar, 400 µm) reveals normal heart structure. (B) Heart to body weight and heart
to tibia length ratios of Inpp5f+/+ (n = 8) and Inpp5f -/- (n = 12) mice at 2 month of age.
(C) Heart to body weight and heart to tibia length ratios of Inpp5f+/+ (n = 4) and
Inpp5f -/- (n = 4) mice at 9 month are shown. NS: not significant.

70

Figure 2.7: Inpp5f-deficient mice are susceptible to agonist-induced cardiac
hypertrophy.

Adapted and modified from (Zhu et al., 2009).
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Figure 2.7: Inpp5f-deficient mice are susceptible to agonist-induced cardiac
hypertrophy.
(A) Wild-type and Inpp5f-/- littermates were subjected to chronic infusion of saline or
ISO for 14 days. Heart weight to body weight and heart weight to tibia length ratios
(± s.d.) were determined. (B) Transcripts for Nppa, Nppb and Myh7 were detected by
real-time quantitative PCR in hearts from wild-type and Inpp5f-/- mice following
chronic infusion of saline or ISO. The values are expressed as the fold change in
transcript abundance (± s.d.) compared to wild-type mice. (C) Wheat germ agglutinin
(WGA) staining shows increased myocyte size in Inpp5f-/- compared to wild-type
hearts (scale bar, 25 µm). (D)Trichrome staining demonstrates more fibrosis (blue) in
Inpp5f-/- hearts treated with ISO (scale bar, 150 µm,) compared to control. (E) Western
blots from neonatal cardiomyocytes treated with or without 10 µM ISO for 10 min are
shown; Gapdh is shown as a loading control.
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Figure 2.8: PIP3 levels are altered in the Inpp5f knockout mice.

Adapted and modified from (Zhu et al., 2009). The mass spec data was obtained in
collaboration with Dr Andrew Quong at Tomas Jefferson University.

73

Figure 2.8: PIP3 levels are altered in the Inpp5f knockout mice.
(A) Mass spec results from lipid extracts of 4 heart samples. Peak 886 (red circle)
represents PIP3. (B) PIP3 levels, normalized to heart weight, in the Inpp5f-/- and
wildtype hearts after 30 min of 100 nM IGF-1 stimulation were assayed as indicated
in “Materials and Methods”.
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Figure 2.9: Generation of Inpp5f transgenic mice.

Adapted and modified from (Zhu et al., 2009).
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Figure 2.9: Generation of Inpp5f transgenic mice.
(A) Schematic representation of the Inpp5f transgenic constructs. (B) PCR genotyping
result for both constructs. 6 lines for IRES-EGFP and 2 lines for Flag construct are
shown. 1 positive control and 2 negative controls are also shown. (C) Western blot
analysis of myocardium from 2-month-old wild-type and Inpp5f-Tg mice.
Transgenically expressed Inpp5f was epitope-tagged and was detected using an Inpp5f
antibody and a Flag antibody. Arrow: Inpp5f protein. (D) Western Blot to detect the
expression of GFP. Heart protein lysates from 6 lines of IRES-EGFP were extracted
and probed with GFP antibody. The last lane is a positive control showing the
expression of GFP.
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Figure 2.10: Inpp5f-Tg mice are resistant to agonist-induced cardiac hypertrophy.

Adapted and modified from (Zhu et al., 2009).
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Figure 2.10: Inpp5f-Tg mice are resistant to agonist-induced cardiac hypertrophy.
(A) Wild-type and Inpp5f-Tg littermates were subjected to chronic infusion of saline
or ISO for 14 days. Heart weight to body weight and heart weight to tibia length ratios
(± s.d.) were determined. (B) Transcripts for Nppa, Nppb and Myh7 were detected by
real-time quantitative PCR from hearts of wild-type and Inpp5f-Tg mice following
chronic infusion of saline or ISO. The values are expressed as the fold change in
transcript abundance (± s.d.) compared to wild-type mice. (C) Western blots of
myocardium from 2-month-old wild-type and Inpp5f-Tg mice subjected to infusion of
saline or ISO for 14 days. Gapdh is shown as a loading control.
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Figure 2.11: Inpp5f has a Sac domain and it has the conserved catalytic motifs.
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Figure 2.11: Inpp5f has a Sac domain and it has the conserved catalytic motifs.
The Sac domain contains seven highly conserved motifs, including the putative
catalytic RXNCXDCLDRTN motif (conserved motif 6, shown in red). These are
shown for the human Inpp5f, mouse Inpp5f and the yeast Sac domain-containing
proteins Sac1p and Inp51p.
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Figure 2.12: Inpp5f does not interact with PDK1.
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Figure 2.12: Inpp5f does not interact with PDK1 . (A) Western blot shows the
expression of two proteins in transfected Cos7 cells. (B) The proteins were extracted
from transfected Cos7 cells. Co-immunoprecipitation was performed with an antiMyc antibody. Inpp5f did not interact with PDK1 when immunoprecipated with an
anti-Myc antibody and detected with anti-Flag antibody. Input control is shown on the
left. Immunoblot (IB) of Myc control is shown at the bottom.
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Chapter 3 Regulation of Gata4 deacetylation and stability by Hdac2
Some of this Chapter has been published in (Trivedi et al.).

3.1 Summary

In chapter 2, I examined the effects of gain and loss of Inpp5f in the heart,
which might function downstream of Hdac2. However, Hdac2 nulls also display
enhanced cardiac myocyte proliferation during embryonic stages, which I did not
observe in Inpp5f mutant mice. This suggests that mechanisms unrelated to Inpp5f
might be responsible for the embryonic phenotypes of Hdac2 nulls. In this chapter, I
describe that Hdac2 and Gata4 physically interact and I map the Gata4 interaction
domain. I also investigate the function of acetylation on Gata4 stability.

3.2 Introduction

Gata4 is one of the earliest genes expressed by specified cardiac precursors at
the cardiac crescent stage of the mouse development (Arceci et al., 1993; Kelley et al.,
1993). Global loss of Gata4 in mice causes embryonic lethality at E9.5 as a result of
severe defects in the extra-embryonic endoderm and aberrant heart and foregut
morphogenesis (Kuo et al., 1997; Molkentin et al., 1997). Studies involving tissuespecific loss of Gata4 in murine cardiac myocytes have demonstrated a critical role
for Gata4 in embryonic myocyte proliferation (Zeisberg et al., 2005). Mice lacking
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Gata4 in the anterior heart field (AHF), for example, die by E13.5 due to significant
right ventricular and interventricular septal myocyte proliferation defects (Rojas et al.,
2008). Gata4-null cardiomyocytes show down-regulation of a wide array of cell cycle
associated genes, some of which are direct transcriptional targets of Gata4, including
cyclinD2 and cdk4 (Rojas et al., 2008).

Recently, we have shown that global loss of HDAC2 results in partial perinatal
lethality due to cardiac developmental defects that include enhanced cardiac myocyte
proliferation (Trivedi et al., 2007). Microarray and RT-PCR analysis suggested that
several cell cycle genes were up-regulated in Hdac2 null hearts at E16.5, including
transcripts of known Gata4 targets, cyclin-D2 and cdk4. Interestingly, Gata4 protein
levels were unaltered in the knockout hearts (unpublished data).

Gata4 transcriptional activity is known to be regulated by post-translational
modification including acetylation, phosphorylation and sumoylation (Kawamura et
al., 2005; Liang et al., 2001a; Wang et al., 2004). For example, the histone acetyl
transferase (HAT) p300 is able to acetylate Lys311, 318, 320, and 322 of Gata4,
resulting in enhanced DNA binding and transcriptional activity. In transgenic mice,
p300 over-expression in the heart induces Gata4 acetylation and cardiac hypertrophy
(Miyamoto et al., 2006; Yanazume et al., 2003a). Interestingly, p300 null mice die at
E9.5 exhibiting defects in proliferation and cardiac development (Yao et al., 1998).
Mechanisms for Gata4 deacetylation have, to our knowledge, not been previously
described. This leads us to hypothesize that Hdac2 might deacetylate Gata4 and thus
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regulates it transcriptional activity. As an initial step to test this hypothesis, I
investigated the interaction between Gata4 and Hdac2. My results suggest that Gata4
is able to interact with Hdac2 and the lysine rich domain of is responsible for the
interaction.

The present study focused on the role of Hdac2 during embryonic cardiac
development. However, our prior studies have implicated important roles for Hdac2
in the adult heart (Kook et al., 2003; Trivedi et al., 2007). Gata4 also functions in
homeostasis of the adult myocardium, and alterations in transcriptional activity,
including those regulated by p300-mediated acetylation of Gata4, affect adult cardiac
hypertrophy (Dai and Markham, 2001; Hirai et al., 2004; Yanazume et al., 2003a;
Yanazume et al., 2003b). However, the model presented here to explain the roles of
Hdac2 and Gata4 in regulation of embryonic myocardial proliferation cannot easily
explain the roles for these proteins during adult cardiac hypertrophic processes.
Hdac2 deficiency results in resistance to cardiac hypertrophy. Cardiac hypertrophy is
generally associated with enhanced Gata4 activity, which drives cardiac structural
gene expression. A simple extension of the model presented here would suggest that
loss of Hdac2 would result in enhanced Gata4 activity, which is not consistent with
the adult phenotypes.

However, we have noted a dramatic loss of Gata4 protein in

newborn mice lacking Hdac2 (unpublished data), suggesting that hyper-acetylation
results in protein degradation, with resulting loss of Gata4 activity. This would be
consistent with the adult phenotypes we have observed. Actually, a previous study has
provided evidence that acetylated GATA-1 is targeted for degradation via the
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ubiquitin/proteasome pathway and activation by acetylation simultaneously marks
GATA-1 for degradation (Hernandez-Hernandez et al., 2006). The other part of my
study is to elucidate the mechanisms by which acetylation of Gata4 leads to
degradation. My preliminary results suggest that deacetylation of Gata4 by Hdac2
stabilizes Gata4.

3.3 Results

3.3.1 Hdac2 and Gata4 physically interact

Other Gata factors have been shown to be able to recruit Hdacs to regulate gene
expression (Cantor and Orkin, 2005; Hong et al., 2005; Svensson et al., 1999; Tsang
et al., 1997). For example, Hdac3 interacts with Gata2 to regulate transcriptional
repression in hematopoietic progenitor cells (Ozawa et al., 2001). Gata1 recruits
Hdac5 leading to reduced Gata1 transcriptional activity (Watamoto et al., 2003). In
order to test if Gata4 and Hdac2 can physically interact with each other, I transfected
293 cells with HA-tagged Gata4. Total lysates were immunoprecipitated by anti-HA
antibody to immunoprecipitate Gata4 and Western blot analysis was performed with
Hdac2 antibody. The data suggest that Gata4 and Hdac2 can interact (Fig 3.1).
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3.3.2 The interaction between Hdac2 and Gata4 requires the lysine rich domain
of Gata4

The protein structure for Gata4 has been widely studied. It contains a domain of
two adjacent zinc fingers (Cys-X2-Cys-X17-Cys-X2-Cys) that directs preferential
binding to the nucleotide sequence element 5’-(A/T)GATA(A/G)-3’ of target gene
promoters (Pikkarainen et al., 2004). A lysine rich motif is present in between the two
zinc fingers and two separate transcriptional activation domains are present within the
N terminus of the protein (Morrisey et al., 1997). In order to identify the Hdac2
interaction domain in Gata4, eight Gata4 N-terminal deletion constructs and four Cterminal deletion constructs were made (Fig 3.2A). Expression analysis shows that
three of the N-terminal deletion constructs and all four C-terminal deletion constructs
expressed (Fig 3.2B). Co-immunoprecipitation experiments showed that all seven
expressed constructs were able to interact with Hdac2 (Fig 3.3).

Because all

constructs have a common region amino acid 241-274 (Fig 3.2A), I hypothesized that
this is the region that is responsible for the interaction. I then tried to optimize the
transfection conditions for two N-terminal deletion constructs which do not contain
region 241-274 (∆265, ∆294). However, by adjusting the DNA/superfect ratio and
incubation time, I failed to detect any expression (data not shown). Similarly, an Nterminal deletion construct with the first 240 aa did not express either (data not
shown). I then made an internal deletion construct in which amino acids 241-274 were
absent using a technique called splicing overlap extension PCR (Fig 3.4A). I
confirmed the expression of the protein by Western blot (Fig 3.4B). However, the
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expression level of this construct is much lower than the full length construct. I
optimized the transfected DNA amount, DNA/superfect ratio as well as incubation
time. Unfortunately, I found that these factors did not improve the expression level
(Fig 3.5). Therefore, I diluted the full length Gata4 transfected cell lysate using the
untransfected lysate so that the expression levels of the full length Gata4 and the
internal deletion are similar (Fig 3.6A). This construct was unable to bind Hdac2 (Fig
3.6B). Therefore, our data suggest that Gata4 is able to interact with Hdac2 and the
lysine rich motif 241-274 in Gata4 is responsible for this interaction.

3.3.3 Deacetylation of Gata4 by Hdac2 stabilizes Gata4

I hypothesized that acetylation of Gata4 positively signals ubiquitination and
degradation in the heart. I first transfected H9c2 cells, a cardiomyocyte cell line, with
HA-tagged Gata4 and then treated them with cycloheximide (CHX) after 48 hours to
inhibit further protein synthesis. I measured Gata4 decay by Western blots and found
that after 9 hrs, the protein disappeared by half and after 28 hrs, it was almost
completely degraded (Fig 3.7). However, one caveat for this approach is that the
protein half-life is measured when overall protein synthesis is abrogated and thus may
not reflect the actual turnover rate under normal growth conditions. The stability and
abundance of the proteolytic enzymes themselves might also be affected, which
further complicates the accurate measurement of protein turnover rate. Therefore, I
also used pulse chase as an alternative method, which imposes minimal disruption
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with normal cell growth and metabolism. H9c2 cells were transfected with HA-Gata4
and cells were metabolically labeled for 30 min with [35S] methionine/cysteine. The
cells were harvested after 0, 2, 6, 11h of chase. This experiment gave me the time
frame to measure Gata4 stability. The result suggested that after 2 h of chase, the
amount of Gata4 showed a reduction of ~70% (Fig 3.8A). I then hypothesized that cotransfection with Hdac2 leads to increased Gata4 stability. Western blot showed overexpression of Hdac2 in the co-transfected cells (Fig 3.8C), while Gata4 is expressed at
equal amount (data not shown). Preliminary pulse chase results suggest that Hdac2
stabilizes Gata4 though this experiment needs to be repeated for statistical analysis
(Fig 3.8B).
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3.4 Discussion

In this chapter, I demonstrated that Gata4 is able to interact with Hdac2 and the
lysine rich domain located between the two zinc fingers is necessary for interaction.
My preliminary results also suggest that deacetylation of Gata4 by Hdac2 might play
a role in Gata4 stability.

Gata4 contains two distinct zinc finger domains and a C-terminal nuclear
localization sequence that together constitute the DNA binding and protein-protein
interaction domain (Molkentin, 2000). Gata4 also contains two transcriptional
activation domains in the N-terminus (Pikkarainen et al., 2004). Gata4 has been
shown to cooperate with a number of other transcription factors and co-activators.
Specifically, the C-terminal zinc finger domain has been found to interact physically
with several other factors to regulate cardiac gene promoters including p300, dHAND,
Nkx-2.5 and NFAT (Dai et al., 2002; Dai and Markham, 2001; Lee et al., 1998;
Molkentin et al., 1998). However, a co-repressor protein FOG-2 (friend of Gata-2)
interacts with N-terminal zinc finger, and Gata6 may require both zinc fingers for
their interaction (Charron et al., 1999; Lu et al., 1999; Svensson et al., 2000; Svensson
et al., 1999; Tevosian et al., 1999). My studies identify the lysine rich domain located
between the two zinc fingers as the region necessary for interaction with Hdac2.

Previous reports have indicated that Gata factors can recruit Hdacs to target
genes, either by directly interacting or by associating with Fog proteins that can
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recruit the NuRD complex containing Hdac1 and Hdac2 (Cantor and Orkin, 2005;
Hong et al., 2005; Svensson et al., 1999; Tsang et al., 1997). For example, interaction
of Hdac3 with Gata2 leads to transcriptional repression of Gata2 in hematopoietic
progenitor cells (Ozawa et al., 2001). Similarly, Hdac5 interacts with Gata1 and
represses its transcriptional activity (Watamoto et al., 2003). In each case, Hdac
function suppresses Gata dependent transcriptional activity. Although it was generally
assumed that Hdac-mediated transcriptional repression of Gata activity was mediated
by histone deacetylation and chromatin remodeling, it will be interesting to re-address
this question in light of our results to determine if other Gata proteins are regulated by
Hdacs via direct deacetylation.

Acetylation has been shown regulate protein stability in two opposing ways.
Lysines are targets for both acetylation and ubiquitination. Therefore, acetylation can
stabilize proteins by preventing subsequent ubiquitination (Kouzarides, 2000) as
demonstrated for both p53 (Li et al., 2002) and Smad7 (Gronroos et al., 2002).
However, the opposite possibility also exists: acetylation at some lysines might
positively signal ubiquitination at other lysines to thus cause protein loss. For example,
acetylated GATA-1 is targeted for degradation via the ubiquitin/proteasome pathway
and activation by acetylation simultaneously marks GATA-1 for degradation
(Hernandez-Hernandez et al., 2006). Therefore, a lysine mutated construct of Gata4 is
of limited use in studying the effect of acetylation on Gata4 stability. In my study, I
used Hdac2 co-transfection with Gata4. Alternative methods such as p300 cotransfection and Hdac2 inhibitor can also be performed to examine the effect of
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acetylation on Gata4 stability.

3.5 Materials and methods
Immunoprecipitation. 293 cells were homogenized in immunoprecipitation buffer
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, 1 mM
DTT) containing 1 mM PMSF, phosphatase inhibitors (Sigma), and protease
inhibitors mixture (Sigma). The samples were sonicated five times for 3 s. The lysate
was collected by centrifugation at 16,000 X g for 10 min at 4°C. Pre-cleared lysates
with beads were incubated with primary antibodies for 16 h at 4°C. After incubation
for 1 h at 4°C with beads, immunocomplexes were collected, washed three times with
immunoprecipitation buffer at 4°C, and applied to 4-12% SDS-polyacrylamide gels
for Western blot analysis.

Western blotting. Tissue lysates were prepared in lysis buffer consisting of 20 mM
Tris HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100,
1 µg/ml leupeptin, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM βglycerophosphate. 1mM PMSF was added before use. Samples were separated by
SDS-PAGE and transferred to PVDF membranes. We used antibodies to Gapdh
(1:5,000 dilution, Chemicon, MAB374), HA (1:1000 dilution, SantaCruz) and Hdac2
(1:1000 dilution, Invitrogen). Primary antibody binding was visualized by using the
Western Breeze Kit (Invitrogen) according to the manufacturer’s instructions.
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Transient transfections. H9c2 myoblasts and 293 cells were transfected with
SuperFect reagent (Qiagen) as per manufacturer's protocol.

Plasmids and deletion constructs cloning. Plasmids for expression of Hdac2 and
Gata4 are previously described (Durocher et al., 1997; Kook et al., 2003; Trivedi et al.,
2007). Various deletion mutants of HA tagged Gata4 cDNA were created by PCR
amplification, sequence verified, and subcloned into the pGC eukaryotic expression
vector. Primers sequences for Gata4 deletion constructs are as follows:
N terminal deletion constructs:
Reverse primer is 5'-TTACGCGGTGATTATGTCCC-3'
Forward primer:
∆80:

5'-

GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGGACCCAGCAGGGTA
G-3'
∆129:

5'-

GCCACCatgTACCCATACGATGTTCCAGATTACGCTGCAGCCTACAGCAGTAG
C-3'
∆183:

5'-

GCCACCatgTACCCATACGATGTTCCAGATTACGCTTTCGACAGCCCAGTCCT
G-3'
∆209:
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5'GCCACCatgTACCCATACGATGTTCCAGATTACGCTTTCTCAGAAGGCAGAG
AGTGT-3'
∆240:

5'-

GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGCCTCTACCACAAGAT
GAAT-3'
∆265:
5'GCCACCatgTACCCATACGATGTTCCAGATTACGCTGTAGGCCTCTCCTGTGC
C-3'
∆294:
5'GCCACCatgTACCCATACGATGTTCCAGATTACGCTGGCCTCTACATGAAGCT
CC-3'
∆329:
5'GCCACCatgTACCCATACGATGTTCCAGATTACGCTCCAGCAGGTCCTCCTGG
-3'
C terminal deletion constructs:
Forward

primer

is

5'-

GCCACCatgTACCCATACGATGTTCCAGATTACGCTTACCAAAGCCTGGCTAT
G-3'
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Reverse primer:
∆391-440: 5'-TTAGCCGGACACAGTACTGAATGT-3'
∆337-440: 5'-TTACTCGCCAGGAGGACCTG-3'
∆311-440: 5'-TTACCGCATTGCAAGAGGCCT-3'
∆275-440: 5'-TTACTGGCAGTTGGCACAGGA-3'

Splicing overlap extension PCR. The PCR methods are previously described
(Warrens et al., 1997). Primers sequences for the splicing overlap extension PCR are
as follows:
Gata4 primer A: 5’-ATG TAC CAA AGC CTG GCT AT-3’
Gata4 primer B hybrid: 5’-CAG TGT GGT GGT GGT AGT ACA GGC GTT GCA
TAG GTA-3’
Gata4 primer C hybrid: 5’-TAC CTA TGC AAC GCC TGT ACT ACC ACC ACC
ACA CTG-3’
Gata4 primer D: 5’-TTA CGC GGT GAT TAT GTC CC-3’

Pulse chase. Cells were starved for 30 min in 2 ml of methionine/cysteine-free
medium (Invitrogen) at 37oC, metabolically labeled for 30 min with 125 µCi/ml of 35S
methionine/cysteine (pulse), washed free of unbound radioactive amino acids, and
incubated in prewarmed complete medium (chase). At the indicated time points, the
cells were disrupted in ice-cold lysis buffer and immunoprecipitated with anti-HA
antibody. Proteins were subjected to SDS-PAGE. Labeled proteins were visualized
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and quantitatively analyzed with phosphor imager.
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Figure 3.1: Hdac2 and Gata4 physically interact.

97

Figure 3.1: Hdac2 and Gata4 physically interact.
293 cells were transfected with HA-Gata4. Immunoprecipitation were performed by
anti- HA antibody to immunoprecipitate Gata4 and western blot analysis was
performed with Hdac2 antibody to detect the endogenous Hdac2. n.s. non-specific
band.
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Figure 3.2: Generation of 12 Gata4 deletion constructs.

Adapted and modified from (Trivedi et al.).
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Figure 3.2: Generation of 12 Gata4 deletion constructs.
(A) Schematic representation of Gata4 and deletion constructs. (B) Western blot was
performed to examine the expression of the 12 deletion constructs. 7 constructs were
expressed.
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Figure 3.3: Hdac2 is able to interact with all seven deletion constructs.

Adapted and modified from (Trivedi et al.).
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Figure 3.3: Hdac2 is able to interact with all seven deletion constructs. Total
lysates from Gata4 or various Gata4 deletion constructs transfected 293 cells were
immunoprecipitated with anti-HA antibody and Western blot analysis was performed
with anti-Hdac2 antibody to detect endogenous Hdac2. n.s. - non-specific.
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Figure 3.4: Generation of a Gata4 internal deletion construct ∆241-274.

103

Figure 3.4: Generation of a Gata4 internal deletion construct ∆241-274. (A) The
schematic representation of splicing overlap extension PCR. The details are discussed
in the materials and methods section. cDNAs are represented lined as bars. Modified
from (Warrens et al., 1997). (B) The internal deletion construct is expressed though at
a much lower level as detected by Western blot. The H9c2 cells were transfected with
different amounts of DNA as indicated in the figure.
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Figure 3.5: Optimization of ∆241-274 construct transfection conditions.
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Figure 3.5: Optimization of ∆241-274 construct transfection conditions. DNA
amounts, DNA/Superfect ratios and incubation times were adjusted to increase the
construct expression.
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Figure 3.6: The internal deletion construct ∆241-274 was unable to interact with
Hdac2.
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Figure 3.6: The internal deletion construct ∆241-274 was unable to interact with
Hdac2. (A) Gata4 full length construct transfected cell lysate was diluted 50 fold with
untransfected lysate. 50 µg total protein was loaded to compare the level of Gata4 and
Hdac2. (B) Total lysates from Gata4 or the internal deletion construct ∆241-274
transfected 293 cells were immunoprecipated with anti-HA antibody and Western blot
analysis was performed with anti-Hdac2 antibody to detect endogenous Hdac2. nsnon specific.

108

Figure 3.7: Blockage of protein synthesis leads to Gata4 degradation.
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Figure 3.7: Blockage of protein synthesis leads to Gata4 degradation.
(A) H9c2 cells were transfected with HA-Gata4. 48 hrs after transfection, the cells
were treated with 10 µg/ml CHX for indicated time periods. The cells were lysed and
the protein lysates were subjected to SDS-PAGE. Western blot was performed using
anti-HA antibody. (B) Quantification of the remaining protein amount.
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Figure 3.8: Co-transfection with Hdac2 stabilizes Gata4.
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Figure 3.8: Co-transfection with Hdac2 stabilizes Gata4. (A) H9c2 cells were
transfected with HA-Gata4. 48 hrs after transfection, the cells were pulse labeled with
35

S and then collected at indicated time points. The protein lysates were

immunoprecipitated with anti-HA antibody and proteins were subjected to SDSPAGE. Labeled proteins were visualized with phosphor imager. The quantification is
shown on the right. (B) H9c2 cells were transfected with either HA-Gata4 alone or
HA-Gata4 and Hdac2 both. Pulse chase experiment was performed similarly. (C)
Western blot confirms the over-expression of Hdac2 in the Hdac2 and Gata4 cotransfected cells.
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Chapter 4 Conclusions and Future Directions
4.1 Summary

In this dissertation I have investigated the potential mechanisms of Hdac2 in the
regulation of adult cardiac hypertrophy and embryonic myocyte proliferation. In
chapter 2, I described the function of a poorly described PIP3 5’ phosphatase Inpp5f
in cardiac hypertrophic responsiveness. Our prior work (Trivedi et al., 2007) had
implicated this gene in cardiac hypertrophy because it is regulated by Hdac2, and
Hdac2 deficiency protects against hypertrophy by modulating the Akt pathway. My
work directly tests the functions of Inpp5f via both gain and loss of function studies. I
describe the knockout mouse, and transgenic mice over-expressing Inpp5f in the heart.
In both cases, the mice are normal under basal conditions, but the response to
hypertrophic stimuli are abnormal in terms of cardiac size, myocyte size and gene
expression. This work has important clinical implications. The lack of basal defects
suggests that this phosphatase may be a tractable target for therapeutic intervention
for heart failure. In chapter 3, I studied the potential mechanisms of how Hdac2 might
regulate myocyte proliferation during embryonic development. My preliminary
results suggest that Gata4 may be responsible for the hyper-proliferation defects in
Hdac2 null mice. Hdac2 is able to interact with Gata4. However, since Gata4 also
functions in homeostasis of the adult myocardium and cardiac hypertrophy is
generally associated with enhanced Gata4 activity, the model presented in chapter 3
cannot easily explain its role during adult cardiac hypertrophy. Therefore, in chapter 3,
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I also sought to study the effects of acetylation on Gata4 stability. My preliminary
result suggests that deacetylation stabilizes Gata4. In the absence of Hdac2, Gata4 is
hyper-acetylated leading to more proliferation during embryonic development.
However, hyper-acetylation also marks Gata4 for degradation, which explains the
significant down-regulation of Gata4 levels after birth. Many critical questions still
remain for Inpp5f, Gata4 and Hdac2 and I discuss below several aspects that I feel
worth further investigation.

4.2 Future directions

4.2.1 Inpp5f, a tumor suppressor?

My results suggest that Inpp5f negatively regulates the PI3K/Akt pathway in
vivo. The PI3K/Akt pathway activation initiates a signal transduction cascade that
promotes cell growth, survival and metabolism. The abnormal activation of this
pathway has been validated by epidemiological and experimental studies as an
essential step toward the initiation and maintenance of human tumors (GarciaEcheverria and Sellers, 2008). PTEN, a negative regulator of this pathway, acts as a
tumor suppressor. It is mutated or lost in both heritable and spontaneous cancers.
Germline mutations in PTEN cause autosomal dominant hamartoma tumor syndromes,
whereas sporadic missense mutations occur frequently in central nervous system
(20%), endometrial (39%), colorectal (9%), skin (17%), prostate (14%) and breast
(6%) cancers. Monoallelic loss of PTEN contributes to tumor growth in the context of
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other somatic mutations, and PTEN protein levels correlate with disease severity
(Yuan and Cantley, 2008). When I first got the Inpp5f null mice, I expected that they
would develop some kind of tumors as they age. However, I did not observe any sign
of cancer in these mice. PTEN is considered the principal regulator of basal cellular
PtdIns(3,4,5)P3 levels (Leslie and Downes, 2002). Other PIP3 phosphotases only
allow for greater pathway activity upon Akt stimulation. For example, a single
somatic missense mutation in the phosphatase domain of SHIP1 has been identified in
patients with acute myeloid leukemia which reduced the catalytic activity of SHIP1.
The basal level of Akt phosphorylation was comparable between leukemia cells with
and without the mutation. However, leukemia cells with this mutation showed
enhanced Akt phosphorylation following stimulation (Luo et al., 2003). Besides,
Ship2 has been reported to be a negative regulator of Akt activation. Although loss of
Ship2 is not sufficient to activate Akt, the absence of Ship2 allows for greater activity
upon Akt stimulation (Rommel et al., 2001; Wada et al., 2001). Therefore, it is very
possible that unlike PTEN, which as a stringent regulator attenuates PtdIns(3,4,5)P3
signaling, the 5-phosphatases could function as more subtle modulators of the
PtdIns(3,4,5)P3 signals. It would be interesting to see if Inpp5f increases tumor
development in a Pten null or heterozygous background. Other 5’ phosphatases may
be able to compensate for Inpp5f under the relatively sedentary conditions under nonstressed situations. It would also be informative to test if loss of Inpp5f in
combination with loss of Ship1 and/or Ship2 would result in cancer.

115

4.2.2 Inpp5f, a poorly characterized 5’ phosphatase

In chapter 2, I demonstrated that Inpp5f was able to degrade PIP3 in the heart. I
also identified seven highly conserved motifs and the sixth conserved region of Inpp5f
in both mouse and human has the highly conserved CX5R(T/S) motif. It would be
interesting to see if mutations in the cysteine, arginine and threonine/serine residues
could disrupt its enzymatic activity. We could either transfect the mutated Inpp5f and
measure Akt level or measure PIP3 levels directly by ELISA.

4.2.3 To what extent does Hdac2 regulate hypertrophy through Inpp5f?

In chapter 2, I elucidated the role of Inpp5f in regulating cardiac hypertrophy by
utilizing a gene-trap Inpp5f global knockout mouse model and a cardiac specific overexpression mouse model. My data suggests that Inpp5f transgenic mice were unable
to reactivate fetal genes or to exhibit normal hypertrophic responses while Inpp5f
knockout mice have augmented hypertrophy associated with reactivation of the fetal
gene program. Biochemical analysis indicated that these responses were mediated by
the PI3K/Akt pathway. Furthermore, we have also shown that Hdac2 promotes
cardiac hypertrophy (Trivedi et al., 2007) and that Inpp5f is up-regulated in Hdac2
knockout hearts, both during late gestation and in the adult while it is down-regulated
in Hdac2 transgenic mice that over-express Hdac2 in the heart. Hdac2 can deacetylate
histones at the Inpp5f upstream genomic region, consistent with direct regulation
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(Trivedi et al., 2007). However, it remains unclear whether Hdac2 regulates
hypertrophy partially or entirely via Inpp5f. I performed some preliminary crosses
with Hdac2+/- and Inpp5f -/- to generate Hdac2-/-Inpp5f-/-. Future experiments can
be done to see if these double knockout mice respond differently to hypertrophic
stimuli from the Hdac2 nulls. I predict that these double knockout mice will be
relatively sensitive to hypertrophy and the PI3K/Akt pathway will be activated
compared with the Hdac2-/-. Similarly, Inpp5f transgenic mice can be crossed to
Hdac2 transgenic mice to determine if the double transgenic mice are less susceptible
to hypertrophic stimuli than the Hdac2 transgenic mice.

4.2.4 Does Inpp5f function upstream of Akt?

My results suggest that loss of Inpp5f leads to hyper-activation of the PI3K/Akt
pathway upon stimulation while over-expression of Inpp5f results in down-regulation
of the pathway activity in the heart. I performed Akt+/- and Inpp5f -/- crosses to
address the question if Inpp5f really functions upstream of Akt in vivo. Future
experiments can be done to analyze the double knockout phenotypes. I expect that the
double knockout would be relatively resistant to hypertrophy compared with Inpp5f
single nulls.
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4.2.5 Does Gata4 need Friend of GATA (Fog) to recruit Hdac2?

Most of the protein-protein interactions of GATA factors are mediated by its Cterminal zinc finger, including the interaction with p300, Nkx2.5, NFAT, while the Nterminal zinc finger interacts with Fog transcription factors (Pikkarainen et al., 2004).
My study identifies the lysine rich domain located between the two zinc fingers as the
region necessary for interaction with Hdac2. It is unknown whether this interaction is
direct or requires other co-factors. Gata factors can recruit Hdacs to target genes,
either by directly interacting or by associating with Fog (Friend of Gata) proteins that
can recruit the NuRD complex containing Hdac1 and Hdac2 (Cantor and Orkin, 2005;
Hong et al., 2005; Svensson et al., 1999; Tsang et al., 1997). The lysine rich domain
we identified is very close to the region where Fog interacts with Gata. Therefore, it
would be interesting to investigate if Gata4 requires Fog to interact with Hdac2.
Several mutation screens have been done to identify point mutations in Gata-1 that
disrupt binding to FOG-1 (Crispino et al., 1999; Crispino and Orkin, 2002) and these
residues are highly conserved among all vertebrate GATA factors (Cantor and Orkin,
2005). Experiments can be performed using in vitro translated Gata4 and Hdac2
proteins to test if the interaction is direct or not. Co-IP can also be done in a Fog
expressing cell line using mutated Gata4 that cannot recruit Fog and to see if the
mutant Gata4 can interact with Hdac2 or not.
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4.2.6 Can Hdacs deacetylate other Gata members?

Other Gata family members have also been shown to recruit Hdacs to mediate
transcriptional repression. For example, Hdac3 associates with and represses Gata2 in
hematopoietic progenitor cells (Ozawa et al., 2001). Gata1 interaction with Hdac5
results in reduced Gata1 transcriptional activity (Watamoto et al., 2003). In each case,
Hdac function suppresses Gata dependent transcriptional activity. Although it was
generally assumed that Hdac-mediated transcriptional repression of Gata activity was
mediated by histone deacetylation and chromatin remodeling, it will be interesting to
re-address this question in light of my results to determine if other Gata proteins are
regulated by Hdacs via direct deacetylation.

4.2.7 To what extent does Hdac2 regulates cardiomyocyte proliferation through
Gata4 acetylation?

In chapter 3, I showed that Hdac2 interacted with Gata4. Our lab also
demonstrates that Hdac2 is able to deacetylate Gata4 and in Hdac2 null hearts Gata4
acetylation is increased. Acetylated Gata4 has enhanced DNA binding and
transcriptional ability (Takaya et al., 2008). Several studies have demonstrated a
critical role for Gata4 in embryonic myocyte proliferation (Rojas et al., 2008;
Zeisberg et al., 2005). All this evidence suggests that Hdac2 inhibits cardiomyocyte
proliferation through deacetylating Gata4. However, we did not perform the definitive
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experiments to test this concept. Future work could address this, by crossing Hdac2
nulls with cardiac specific Gata4 nulls. We could expect the myocytes from double
nulls have less proliferation rates than Hdac2 nulls. A cardiac specific Gata4
acetylation deficient (by mutating lysine to alanine) knockin mouse model could also
be generated. These mice can then be crossed with Hdac2 knockouts. Since the
mutated Gata4 could not be acetylated, loss of Hdac2 would not lead to more myocyte
proliferation.

4.3 Concluding remarks

The studies presented here define the mechanisms of Hdac2 in regulating
embryonic heart development and adult heart hypertrophy. I identified two targets of
Hdac2, Inpp5f and Gata4, and I investigated how they contribute to the phenotypes of
Hdac2 nulls. Hdac2 regulates Inpp5f through modifying the histones of its promoter
while it regulates Gata4 through acetylating the Gata4 protein itself. The
characterization of Hdacs and HATs and their various activities has attracted
increasing investigative interest because of their importance in stem and progenitor
cell biology and in cellular reprogramming. It would be exciting to see how these
findings will contribute to the study of embryology to human medicine.
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